#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Identifying functional network changing patterns in individuals at clinical high-risk for psychosis and patients with early illness schizophrenia: A group ICA study Although individuals at clinical high risk (CHR) for psychosis exhibit a psychosis-risk syndrome involving attenuated forms of the positive symptoms typical of schizophrenia (SZ), it remains unclear whether their resting-state brain intrinsic functional networks (INs) show attenuated or qualitatively distinct patterns of functional dysconnectivity relative to SZ patients.
1-1	0-11	Identifying	_
1-2	12-22	functional	_
1-3	23-30	network	_
1-4	31-39	changing	_
1-5	40-48	patterns	_
1-6	49-51	in	_
1-7	52-63	individuals	_
1-8	64-66	at	_
1-9	67-75	clinical	_
1-10	76-85	high-risk	_
1-11	86-89	for	_
1-12	90-99	psychosis	_
1-13	100-103	and	_
1-14	104-112	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-15	113-117	with	_
1-16	118-123	early	_
1-17	124-131	illness	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-18	132-145	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-19	146-147	:	_
1-20	148-149	A	_
1-21	150-155	group	_
1-22	156-159	ICA	_
1-23	160-165	study	_
1-24	166-174	Although	_
1-25	175-186	individuals	_
1-26	187-189	at	_
1-27	190-198	clinical	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
1-28	199-203	high	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
1-29	204-208	risk	_
1-30	209-210	(	http://maven.renci.org/NeuroBridge/neurobridge#ChronicPain
1-31	211-214	CHR	http://maven.renci.org/NeuroBridge/neurobridge#ChronicPain
1-32	215-216	)	http://maven.renci.org/NeuroBridge/neurobridge#ChronicPain
1-33	217-220	for	_
1-34	221-230	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-35	231-238	exhibit	_
1-36	239-240	a	_
1-37	241-255	psychosis-risk	_
1-38	256-264	syndrome	_
1-39	265-274	involving	_
1-40	275-285	attenuated	_
1-41	286-291	forms	_
1-42	292-294	of	_
1-43	295-298	the	_
1-44	299-307	positive	_
1-45	308-316	symptoms	_
1-46	317-324	typical	_
1-47	325-327	of	_
1-48	328-341	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-49	342-343	(	_
1-50	344-346	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
1-51	347-348	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
1-52	349-350	,	_
1-53	351-353	it	_
1-54	354-361	remains	_
1-55	362-369	unclear	_
1-56	370-377	whether	_
1-57	378-383	their	_
1-58	384-397	resting-state	_
1-59	398-403	brain	_
1-60	404-413	intrinsic	_
1-61	414-424	functional	_
1-62	425-433	networks	_
1-63	434-435	(	_
1-64	436-439	INs	_
1-65	440-441	)	_
1-66	442-446	show	_
1-67	447-457	attenuated	_
1-68	458-460	or	_
1-69	461-474	qualitatively	_
1-70	475-483	distinct	_
1-71	484-492	patterns	_
1-72	493-495	of	_
1-73	496-506	functional	_
1-74	507-522	dysconnectivity	_
1-75	523-531	relative	_
1-76	532-534	to	_
1-77	535-537	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-78	538-546	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-79	547-548	.	_

Text=Based on resting-state functional magnetic imaging data from 70 healthy controls (HCs), 53 CHR individuals (among which 41 subjects were antipsychotic medication-naive), and 58 early illness SZ (ESZ) patients (among which 53 patients took antipsychotic medication) within five years of illness onset, we estimated subject-specific INs using a novel group information guided independent component analysis (GIG-ICA) and investigated group differences in INs.
2-1	549-554	Based	_
2-2	555-557	on	_
2-3	558-571	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
2-4	572-582	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
2-5	583-591	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
2-6	592-599	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
2-7	600-604	data	_
2-8	605-609	from	_
2-9	610-612	70	_
2-10	613-620	healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
2-11	621-629	controls	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
2-12	630-631	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
2-13	632-635	HCs	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
2-14	636-637	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
2-15	638-639	,	_
2-16	640-642	53	_
2-17	643-646	CHR	http://maven.renci.org/NeuroBridge/neurobridge#ChronicPain
2-18	647-658	individuals	_
2-19	659-660	(	_
2-20	661-666	among	_
2-21	667-672	which	_
2-22	673-675	41	_
2-23	676-684	subjects	_
2-24	685-689	were	_
2-25	690-703	antipsychotic	_
2-26	704-720	medication-naive	_
2-27	721-722	)	_
2-28	723-724	,	_
2-29	725-728	and	_
2-30	729-731	58	_
2-31	732-737	early	http://maven.renci.org/NeuroBridge/neurobridge#ResearchStudy
2-32	738-745	illness	http://maven.renci.org/NeuroBridge/neurobridge#EpworthSleepinessScale
2-33	746-748	SZ	http://maven.renci.org/NeuroBridge/neurobridge#EpworthSleepinessScale
2-34	749-750	(	http://maven.renci.org/NeuroBridge/neurobridge#EpworthSleepinessScale
2-35	751-754	ESZ	http://maven.renci.org/NeuroBridge/neurobridge#EpworthSleepinessScale
2-36	755-756	)	http://maven.renci.org/NeuroBridge/neurobridge#EpworthSleepinessScale
2-37	757-765	patients	http://maven.renci.org/NeuroBridge/neurobridge#EpworthSleepinessScale
2-38	766-767	(	_
2-39	768-773	among	_
2-40	774-779	which	_
2-41	780-782	53	_
2-42	783-791	patients	_
2-43	792-796	took	_
2-44	797-810	antipsychotic	_
2-45	811-821	medication	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus
2-46	822-823	)	_
2-47	824-830	within	_
2-48	831-835	five	_
2-49	836-841	years	_
2-50	842-844	of	_
2-51	845-852	illness	_
2-52	853-858	onset	_
2-53	859-860	,	_
2-54	861-863	we	_
2-55	864-873	estimated	_
2-56	874-890	subject-specific	_
2-57	891-894	INs	_
2-58	895-900	using	_
2-59	901-902	a	_
2-60	903-908	novel	_
2-61	909-914	group	_
2-62	915-926	information	_
2-63	927-933	guided	_
2-64	934-945	independent	_
2-65	946-955	component	_
2-66	956-964	analysis	_
2-67	965-966	(	_
2-68	967-974	GIG-ICA	_
2-69	975-976	)	_
2-70	977-980	and	_
2-71	981-993	investigated	_
2-72	994-999	group	_
2-73	1000-1011	differences	_
2-74	1012-1014	in	_
2-75	1015-1018	INs	_
2-76	1019-1020	.	_

Text=We found that when compared to HCs, both CHR and ESZ groups showed significant differences, primarily in default mode, salience, auditory-related, visuospatial, sensory-motor, and parietal INs.
3-1	1021-1023	We	_
3-2	1024-1029	found	_
3-3	1030-1034	that	_
3-4	1035-1039	when	_
3-5	1040-1048	compared	_
3-6	1049-1051	to	_
3-7	1052-1055	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
3-8	1056-1057	,	_
3-9	1058-1062	both	_
3-10	1063-1066	CHR	http://maven.renci.org/NeuroBridge/neurobridge#ChronicPain
3-11	1067-1070	and	_
3-12	1071-1074	ESZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
3-13	1075-1081	groups	_
3-14	1082-1088	showed	_
3-15	1089-1100	significant	_
3-16	1101-1112	differences	_
3-17	1113-1114	,	_
3-18	1115-1124	primarily	_
3-19	1125-1127	in	_
3-20	1128-1135	default	_
3-21	1136-1140	mode	_
3-22	1141-1142	,	_
3-23	1143-1151	salience	_
3-24	1152-1153	,	_
3-25	1154-1170	auditory-related	_
3-26	1171-1172	,	_
3-27	1173-1185	visuospatial	_
3-28	1186-1187	,	_
3-29	1188-1201	sensory-motor	_
3-30	1202-1203	,	_
3-31	1204-1207	and	_
3-32	1208-1216	parietal	_
3-33	1217-1220	INs	_
3-34	1221-1222	.	_

Text=Our findings suggest that widespread INs were diversely impacted.
4-1	1223-1226	Our	_
4-2	1227-1235	findings	_
4-3	1236-1243	suggest	_
4-4	1244-1248	that	_
4-5	1249-1259	widespread	_
4-6	1260-1263	INs	_
4-7	1264-1268	were	_
4-8	1269-1278	diversely	_
4-9	1279-1287	impacted	_
4-10	1288-1289	.	_

Text=More than 25% of voxels in the identified significant discriminative regions (obtained using all 19 possible changing patterns excepting the no-difference pattern) from six of the 15 interrogated INs exhibited monotonically decreasing Z-scores (in INs) from the HC to CHR to ESZ, and the related regions included the left lingual gyrus of two vision-related networks, the right postcentral cortex of the visuospatial network, the left thalamus region of the salience network, the left calcarine region of the fronto-occipital network and fronto-parieto-occipital network.
5-1	1290-1294	More	_
5-2	1295-1299	than	_
5-3	1300-1302	25	_
5-4	1303-1304	%	_
5-5	1305-1307	of	_
5-6	1308-1314	voxels	_
5-7	1315-1317	in	_
5-8	1318-1321	the	_
5-9	1322-1332	identified	_
5-10	1333-1344	significant	_
5-11	1345-1359	discriminative	_
5-12	1360-1367	regions	_
5-13	1368-1369	(	_
5-14	1370-1378	obtained	_
5-15	1379-1384	using	_
5-16	1385-1388	all	_
5-17	1389-1391	19	_
5-18	1392-1400	possible	_
5-19	1401-1409	changing	_
5-20	1410-1418	patterns	_
5-21	1419-1428	excepting	_
5-22	1429-1432	the	_
5-23	1433-1446	no-difference	_
5-24	1447-1454	pattern	_
5-25	1455-1456	)	_
5-26	1457-1461	from	_
5-27	1462-1465	six	_
5-28	1466-1468	of	_
5-29	1469-1472	the	_
5-30	1473-1475	15	_
5-31	1476-1488	interrogated	_
5-32	1489-1492	INs	_
5-33	1493-1502	exhibited	_
5-34	1503-1516	monotonically	_
5-35	1517-1527	decreasing	_
5-36	1528-1536	Z-scores	_
5-37	1537-1538	(	_
5-38	1539-1541	in	_
5-39	1542-1545	INs	_
5-40	1546-1547	)	_
5-41	1548-1552	from	_
5-42	1553-1556	the	_
5-43	1557-1559	HC	_
5-44	1560-1562	to	_
5-45	1563-1566	CHR	_
5-46	1567-1569	to	_
5-47	1570-1573	ESZ	_
5-48	1574-1575	,	_
5-49	1576-1579	and	_
5-50	1580-1583	the	_
5-51	1584-1591	related	_
5-52	1592-1599	regions	_
5-53	1600-1608	included	_
5-54	1609-1612	the	_
5-55	1613-1617	left	_
5-56	1618-1625	lingual	_
5-57	1626-1631	gyrus	_
5-58	1632-1634	of	_
5-59	1635-1638	two	_
5-60	1639-1653	vision-related	_
5-61	1654-1662	networks	_
5-62	1663-1664	,	_
5-63	1665-1668	the	_
5-64	1669-1674	right	_
5-65	1675-1686	postcentral	_
5-66	1687-1693	cortex	_
5-67	1694-1696	of	_
5-68	1697-1700	the	_
5-69	1701-1713	visuospatial	_
5-70	1714-1721	network	_
5-71	1722-1723	,	_
5-72	1724-1727	the	_
5-73	1728-1732	left	_
5-74	1733-1741	thalamus	_
5-75	1742-1748	region	_
5-76	1749-1751	of	_
5-77	1752-1755	the	_
5-78	1756-1764	salience	_
5-79	1765-1772	network	_
5-80	1773-1774	,	_
5-81	1775-1778	the	_
5-82	1779-1783	left	_
5-83	1784-1793	calcarine	_
5-84	1794-1800	region	_
5-85	1801-1803	of	_
5-86	1804-1807	the	_
5-87	1808-1824	fronto-occipital	_
5-88	1825-1832	network	_
5-89	1833-1836	and	_
5-90	1837-1861	fronto-parieto-occipital	_
5-91	1862-1869	network	_
5-92	1870-1871	.	_

Text=Compared to HCs and CHR individuals, ESZ patients showed both increasing and decreasing connectivity, mainly hypo-connectivity involving 15% of the altered voxels from four INs.
6-1	1872-1880	Compared	_
6-2	1881-1883	to	_
6-3	1884-1887	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
6-4	1888-1891	and	_
6-5	1892-1895	CHR	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
6-6	1896-1907	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
6-7	1908-1909	,	_
6-8	1910-1913	ESZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-9	1914-1922	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-10	1923-1929	showed	_
6-11	1930-1934	both	_
6-12	1935-1945	increasing	_
6-13	1946-1949	and	_
6-14	1950-1960	decreasing	_
6-15	1961-1973	connectivity	_
6-16	1974-1975	,	_
6-17	1976-1982	mainly	_
6-18	1983-2000	hypo-connectivity	_
6-19	2001-2010	involving	_
6-20	2011-2013	15	_
6-21	2014-2015	%	_
6-22	2016-2018	of	_
6-23	2019-2022	the	_
6-24	2023-2030	altered	_
6-25	2031-2037	voxels	_
6-26	2038-2042	from	_
6-27	2043-2047	four	_
6-28	2048-2051	INs	_
6-29	2052-2053	.	_

Text=The left supplementary motor area from the sensory-motor network and the right inferior occipital gyrus in the vision-related network showed a common abnormality in CHR and ESZ groups.
7-1	2054-2057	The	_
7-2	2058-2062	left	_
7-3	2063-2076	supplementary	_
7-4	2077-2082	motor	_
7-5	2083-2087	area	_
7-6	2088-2092	from	_
7-7	2093-2096	the	_
7-8	2097-2110	sensory-motor	_
7-9	2111-2118	network	_
7-10	2119-2122	and	_
7-11	2123-2126	the	_
7-12	2127-2132	right	_
7-13	2133-2141	inferior	_
7-14	2142-2151	occipital	_
7-15	2152-2157	gyrus	_
7-16	2158-2160	in	_
7-17	2161-2164	the	_
7-18	2165-2179	vision-related	_
7-19	2180-2187	network	_
7-20	2188-2194	showed	_
7-21	2195-2196	a	_
7-22	2197-2203	common	_
7-23	2204-2215	abnormality	_
7-24	2216-2218	in	_
7-25	2219-2222	CHR	http://maven.renci.org/NeuroBridge/neurobridge#ChronicPain
7-26	2223-2226	and	_
7-27	2227-2230	ESZ	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
7-28	2231-2237	groups	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
7-29	2238-2239	.	_

Text=Some brain regions also showed a CHR-unique alteration (primarily the CHR-increasing connectivity).
8-1	2240-2244	Some	_
8-2	2245-2250	brain	_
8-3	2251-2258	regions	_
8-4	2259-2263	also	_
8-5	2264-2270	showed	_
8-6	2271-2272	a	_
8-7	2273-2283	CHR-unique	_
8-8	2284-2294	alteration	_
8-9	2295-2296	(	_
8-10	2297-2306	primarily	_
8-11	2307-2310	the	_
8-12	2311-2325	CHR-increasing	_
8-13	2326-2338	connectivity	_
8-14	2339-2340	)	_
8-15	2341-2342	.	_

Text=In summary, CHR individuals generally showed intermediate connectivity between HCs and ESZ patients across multiple INs, suggesting that some dysconnectivity patterns evident in ESZ predate psychosis in attenuated form during the psychosis risk stage.
9-1	2343-2345	In	_
9-2	2346-2353	summary	_
9-3	2354-2355	,	_
9-4	2356-2359	CHR	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
9-5	2360-2371	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
9-6	2372-2381	generally	_
9-7	2382-2388	showed	_
9-8	2389-2401	intermediate	_
9-9	2402-2414	connectivity	_
9-10	2415-2422	between	_
9-11	2423-2426	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
9-12	2427-2430	and	_
9-13	2431-2434	ESZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-14	2435-2443	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-15	2444-2450	across	_
9-16	2451-2459	multiple	_
9-17	2460-2463	INs	_
9-18	2464-2465	,	_
9-19	2466-2476	suggesting	_
9-20	2477-2481	that	_
9-21	2482-2486	some	_
9-22	2487-2502	dysconnectivity	_
9-23	2503-2511	patterns	_
9-24	2512-2519	evident	_
9-25	2520-2522	in	_
9-26	2523-2526	ESZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
9-27	2527-2534	predate	_
9-28	2535-2544	psychosis	_
9-29	2545-2547	in	_
9-30	2548-2558	attenuated	_
9-31	2559-2563	form	_
9-32	2564-2570	during	_
9-33	2571-2574	the	_
9-34	2575-2584	psychosis	_
9-35	2585-2589	risk	_
9-36	2590-2595	stage	_
9-37	2596-2597	.	_

Text=Hence, these connectivity measures may serve as possible biomarkers to predict schizophrenia progression.
10-1	2598-2603	Hence	_
10-2	2604-2605	,	_
10-3	2606-2611	these	_
10-4	2612-2624	connectivity	_
10-5	2625-2633	measures	_
10-6	2634-2637	may	_
10-7	2638-2643	serve	_
10-8	2644-2646	as	_
10-9	2647-2655	possible	_
10-10	2656-2666	biomarkers	_
10-11	2667-2669	to	_
10-12	2670-2677	predict	_
10-13	2678-2691	schizophrenia	_
10-14	2692-2703	progression	_
10-15	2704-2705	.	_

Text=Highlights This is the first study exploring functional networks in clinical high risk for psychosis using ICA.
11-1	2706-2716	Highlights	_
11-2	2717-2721	This	_
11-3	2722-2724	is	_
11-4	2725-2728	the	_
11-5	2729-2734	first	_
11-6	2735-2740	study	_
11-7	2741-2750	exploring	_
11-8	2751-2761	functional	_
11-9	2762-2770	networks	_
11-10	2771-2773	in	_
11-11	2774-2782	clinical	_
11-12	2783-2787	high	_
11-13	2788-2792	risk	_
11-14	2793-2796	for	_
11-15	2797-2806	psychosis	_
11-16	2807-2812	using	_
11-17	2813-2816	ICA	_
11-18	2817-2818	.	_

Text=Novel group information guided ICA was applied to accurately estimate networks.
12-1	2819-2824	Novel	_
12-2	2825-2830	group	_
12-3	2831-2842	information	_
12-4	2843-2849	guided	_
12-5	2850-2853	ICA	_
12-6	2854-2857	was	_
12-7	2858-2865	applied	_
12-8	2866-2868	to	_
12-9	2869-2879	accurately	_
12-10	2880-2888	estimate	_
12-11	2889-2897	networks	_
12-12	2898-2899	.	_

Text=Multiple networks altered in early schizophrenia and clinical high risk groups.
13-1	2900-2908	Multiple	_
13-2	2909-2917	networks	_
13-3	2918-2925	altered	_
13-4	2926-2928	in	_
13-5	2929-2934	early	_
13-6	2935-2948	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
13-7	2949-2952	and	_
13-8	2953-2961	clinical	_
13-9	2962-2966	high	_
13-10	2967-2971	risk	_
13-11	2972-2978	groups	_
13-12	2979-2980	.	_

Text=Some regions showed step-wise worsening of dysconnectivity from healthy condition to psychosis risk to schizophrenia.
14-1	2981-2985	Some	_
14-2	2986-2993	regions	_
14-3	2994-3000	showed	_
14-4	3001-3010	step-wise	_
14-5	3011-3020	worsening	_
14-6	3021-3023	of	_
14-7	3024-3039	dysconnectivity	_
14-8	3040-3044	from	_
14-9	3045-3052	healthy	_
14-10	3053-3062	condition	_
14-11	3063-3065	to	_
14-12	3066-3075	psychosis	_
14-13	3076-3080	risk	_
14-14	3081-3083	to	_
14-15	3084-3097	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
14-16	3098-3099	.	_

Text=Early schizophrenia and psychosis risk groups also showed common abnormalities.
15-1	3100-3105	Early	_
15-2	3106-3119	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
15-3	3120-3123	and	_
15-4	3124-3133	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
15-5	3134-3138	risk	_
15-6	3139-3145	groups	_
15-7	3146-3150	also	_
15-8	3151-3157	showed	_
15-9	3158-3164	common	_
15-10	3165-3178	abnormalities	_
15-11	3179-3180	.	_

Text=Materials and methods Subjects We analyzed resting-state fMRI data from 70 HCs, 53 CHR individuals, and 58 ESZ patients.
16-1	3181-3190	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
16-2	3191-3194	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
16-3	3195-3202	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
16-4	3203-3211	Subjects	_
16-5	3212-3214	We	_
16-6	3215-3223	analyzed	_
16-7	3224-3237	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
16-8	3238-3242	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
16-9	3243-3247	data	_
16-10	3248-3252	from	_
16-11	3253-3255	70	_
16-12	3256-3259	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
16-13	3260-3261	,	_
16-14	3262-3264	53	_
16-15	3265-3268	CHR	_
16-16	3269-3280	individuals	_
16-17	3281-3282	,	_
16-18	3283-3286	and	_
16-19	3287-3289	58	_
16-20	3290-3293	ESZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
16-21	3294-3302	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
16-22	3303-3304	.	_

Text=Subject demographic and clinical information are presented in Table 1.
17-1	3305-3312	Subject	_
17-2	3313-3324	demographic	_
17-3	3325-3328	and	_
17-4	3329-3337	clinical	_
17-5	3338-3349	information	_
17-6	3350-3353	are	_
17-7	3354-3363	presented	_
17-8	3364-3366	in	_
17-9	3367-3372	Table	_
17-10	3373-3374	1	_
17-11	3375-3376	.	_

Text=There were no significant differences among the three groups in age or gender (see Table 1).
18-1	3377-3382	There	_
18-2	3383-3387	were	_
18-3	3388-3390	no	_
18-4	3391-3402	significant	_
18-5	3403-3414	differences	_
18-6	3415-3420	among	_
18-7	3421-3424	the	_
18-8	3425-3430	three	_
18-9	3431-3437	groups	_
18-10	3438-3440	in	_
18-11	3441-3444	age	_
18-12	3445-3447	or	_
18-13	3448-3454	gender	_
18-14	3455-3456	(	_
18-15	3457-3460	see	_
18-16	3461-3466	Table	_
18-17	3467-3468	1	_
18-18	3469-3470	)	_
18-19	3471-3472	.	_

Text=CHR individuals were recruited from a psychosis-risk research clinic at the University of California, San Francisco (UCSF).
19-1	3473-3476	CHR	http://maven.renci.org/NeuroBridge/neurobridge#ChronicPain
19-2	3477-3488	individuals	_
19-3	3489-3493	were	_
19-4	3494-3503	recruited	_
19-5	3504-3508	from	_
19-6	3509-3510	a	_
19-7	3511-3525	psychosis-risk	_
19-8	3526-3534	research	_
19-9	3535-3541	clinic	_
19-10	3542-3544	at	_
19-11	3545-3548	the	_
19-12	3549-3559	University	_
19-13	3560-3562	of	_
19-14	3563-3573	California	_
19-15	3574-3575	,	_
19-16	3576-3579	San	_
19-17	3580-3589	Francisco	_
19-18	3590-3591	(	_
19-19	3592-3596	UCSF	_
19-20	3597-3598	)	_
19-21	3599-3600	.	_

Text=Individuals recruited to the CHR group met the Criteria of Prodromal Syndromes (COPS) based on a Structured Interview for Prodromal Syndromes (SIPS) administered by trained clinicians.
20-1	3601-3612	Individuals	_
20-2	3613-3622	recruited	_
20-3	3623-3625	to	_
20-4	3626-3629	the	_
20-5	3630-3633	CHR	http://maven.renci.org/NeuroBridge/neurobridge#ChronicPain
20-6	3634-3639	group	_
20-7	3640-3643	met	_
20-8	3644-3647	the	_
20-9	3648-3656	Criteria	_
20-10	3657-3659	of	_
20-11	3660-3669	Prodromal	http://maven.renci.org/NeuroBridge/neurobridge#ProdromalSymptom
20-12	3670-3679	Syndromes	http://maven.renci.org/NeuroBridge/neurobridge#ProdromalSymptom
20-13	3680-3681	(	http://maven.renci.org/NeuroBridge/neurobridge#ProdromalSymptom
20-14	3682-3686	COPS	http://maven.renci.org/NeuroBridge/neurobridge#ProdromalSymptom
20-15	3687-3688	)	http://maven.renci.org/NeuroBridge/neurobridge#ProdromalSymptom
20-16	3689-3694	based	_
20-17	3695-3697	on	_
20-18	3698-3699	a	_
20-19	3700-3710	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
20-20	3711-3720	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
20-21	3721-3724	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
20-22	3725-3734	Prodromal	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
20-23	3735-3744	Syndromes	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
20-24	3745-3746	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
20-25	3747-3751	SIPS	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
20-26	3752-3753	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
20-27	3754-3766	administered	_
20-28	3767-3769	by	_
20-29	3770-3777	trained	_
20-30	3778-3788	clinicians	_
20-31	3789-3790	.	_

Text=The COPS comprises three non-mutually exclusive syndromes: Attenuated Positive Symptom Syndrome (APSS), Brief Intermittent Psychotic Syndrome (BIPS), and/or Genetic Risk and Deterioration Syndrome (GRD).
21-1	3791-3794	The	_
21-2	3795-3799	COPS	_
21-3	3800-3809	comprises	_
21-4	3810-3815	three	_
21-5	3816-3828	non-mutually	_
21-6	3829-3838	exclusive	_
21-7	3839-3848	syndromes	_
21-8	3849-3850	:	_
21-9	3851-3861	Attenuated	http://maven.renci.org/NeuroBridge/neurobridge#PositiveSymptomScale
21-10	3862-3870	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveSymptomScale
21-11	3871-3878	Symptom	http://maven.renci.org/NeuroBridge/neurobridge#PositiveSymptomScale
21-12	3879-3887	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveSymptomScale
21-13	3888-3889	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveSymptomScale
21-14	3890-3894	APSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveSymptomScale
21-15	3895-3896	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveSymptomScale
21-16	3897-3898	,	_
21-17	3899-3904	Brief	http://maven.renci.org/NeuroBridge/neurobridge#BriefIntermittentPsychoticSyndrome
21-18	3905-3917	Intermittent	http://maven.renci.org/NeuroBridge/neurobridge#BriefIntermittentPsychoticSyndrome
21-19	3918-3927	Psychotic	http://maven.renci.org/NeuroBridge/neurobridge#BriefIntermittentPsychoticSyndrome
21-20	3928-3936	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#BriefIntermittentPsychoticSyndrome
21-21	3937-3938	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefIntermittentPsychoticSyndrome
21-22	3939-3943	BIPS	http://maven.renci.org/NeuroBridge/neurobridge#BriefIntermittentPsychoticSyndrome
21-23	3944-3945	)	http://maven.renci.org/NeuroBridge/neurobridge#BriefIntermittentPsychoticSyndrome
21-24	3946-3947	,	_
21-25	3948-3954	and/or	_
21-26	3955-3962	Genetic	_
21-27	3963-3967	Risk	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
21-28	3968-3971	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
21-29	3972-3985	Deterioration	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
21-30	3986-3994	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
21-31	3995-3996	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
21-32	3997-4000	GRD	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
21-33	4001-4002	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
21-34	4003-4004	.	_

Text=In our study, the majority (49/53, 92.5%) of CHR subjects met COPS criteria for APSS.
22-1	4005-4007	In	_
22-2	4008-4011	our	_
22-3	4012-4017	study	_
22-4	4018-4019	,	_
22-5	4020-4023	the	_
22-6	4024-4032	majority	_
22-7	4033-4034	(	_
22-8	4035-4040	49/53	_
22-9	4041-4042	,	_
22-10	4043-4047	92.5	_
22-11	4048-4049	%	_
22-12	4050-4051	)	_
22-13	4052-4054	of	_
22-14	4055-4058	CHR	_
22-15	4059-4067	subjects	_
22-16	4068-4071	met	_
22-17	4072-4076	COPS	_
22-18	4077-4085	criteria	_
22-19	4086-4089	for	_
22-20	4090-4094	APSS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
22-21	4095-4096	.	_

Text=Supplementary Table S1 shows the number and percentage of CHR subjects with each syndrome.
23-1	4097-4110	Supplementary	_
23-2	4111-4116	Table	_
23-3	4117-4119	S1	_
23-4	4120-4125	shows	_
23-5	4126-4129	the	_
23-6	4130-4136	number	_
23-7	4137-4140	and	_
23-8	4141-4151	percentage	_
23-9	4152-4154	of	_
23-10	4155-4158	CHR	_
23-11	4159-4167	subjects	_
23-12	4168-4172	with	_
23-13	4173-4177	each	_
23-14	4178-4186	syndrome	_
23-15	4187-4188	.	_

Text=Ratings of symptom severity in CHR individuals were obtained using the Scale of Prodromal Symptoms (SOPS), an embedded scale within the SIPS.
24-1	4189-4196	Ratings	_
24-2	4197-4199	of	_
24-3	4200-4207	symptom	_
24-4	4208-4216	severity	_
24-5	4217-4219	in	_
24-6	4220-4223	CHR	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
24-7	4224-4235	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
24-8	4236-4240	were	_
24-9	4241-4249	obtained	_
24-10	4250-4255	using	_
24-11	4256-4259	the	_
24-12	4260-4265	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ProdromalSymptom
24-13	4266-4268	of	http://maven.renci.org/NeuroBridge/neurobridge#ProdromalSymptom
24-14	4269-4278	Prodromal	http://maven.renci.org/NeuroBridge/neurobridge#ProdromalSymptom
24-15	4279-4287	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#ProdromalSymptom
24-16	4288-4289	(	http://maven.renci.org/NeuroBridge/neurobridge#ProdromalSymptom
24-17	4290-4294	SOPS	http://maven.renci.org/NeuroBridge/neurobridge#ProdromalSymptom
24-18	4295-4296	)	http://maven.renci.org/NeuroBridge/neurobridge#ProdromalSymptom
24-19	4297-4298	,	_
24-20	4299-4301	an	_
24-21	4302-4310	embedded	_
24-22	4311-4316	scale	_
24-23	4317-4323	within	_
24-24	4324-4327	the	_
24-25	4328-4332	SIPS	_
24-26	4333-4334	.	_

Text=Most of the CHR subjects (41/53; 77%) were antipsychotic medication-naive at the time of scanning.
25-1	4335-4339	Most	_
25-2	4340-4342	of	_
25-3	4343-4346	the	_
25-4	4347-4350	CHR	http://maven.renci.org/NeuroBridge/neurobridge#ChronicPain
25-5	4351-4359	subjects	_
25-6	4360-4361	(	_
25-7	4362-4367	41/53	_
25-8	4368-4369	;	_
25-9	4370-4372	77	_
25-10	4373-4374	%	_
25-11	4375-4376	)	_
25-12	4377-4381	were	_
25-13	4382-4395	antipsychotic	_
25-14	4396-4412	medication-naive	_
25-15	4413-4415	at	_
25-16	4416-4419	the	_
25-17	4420-4424	time	_
25-18	4425-4427	of	_
25-19	4428-4436	scanning	_
25-20	4437-4438	.	_

Text=ESZ patients within five (mean ± standard deviation = 2.08 ± 1.37) years of illness onset were recruited from an early psychosis clinic at UCSF and from community clinics.
26-1	4439-4442	ESZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
26-2	4443-4451	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
26-3	4452-4458	within	_
26-4	4459-4463	five	_
26-5	4464-4465	(	_
26-6	4466-4470	mean	_
26-7	4471-4472	±	_
26-8	4473-4481	standard	_
26-9	4482-4491	deviation	_
26-10	4492-4493	=	_
26-11	4494-4498	2.08	_
26-12	4499-4500	±	_
26-13	4501-4505	1.37	_
26-14	4506-4507	)	_
26-15	4508-4513	years	_
26-16	4514-4516	of	_
26-17	4517-4524	illness	_
26-18	4525-4530	onset	_
26-19	4531-4535	were	_
26-20	4536-4545	recruited	_
26-21	4546-4550	from	_
26-22	4551-4553	an	_
26-23	4554-4559	early	_
26-24	4560-4569	psychosis	_
26-25	4570-4576	clinic	_
26-26	4577-4579	at	_
26-27	4580-4584	UCSF	_
26-28	4585-4588	and	_
26-29	4589-4593	from	_
26-30	4594-4603	community	_
26-31	4604-4611	clinics	_
26-32	4612-4613	.	_

Text=Diagnosis of schizophrenia or schizoaffective disorder in ESZ subjects was verified using the Structured Clinical Interview for DSM-IV (SCID) and symptom severity was assessed using the Positive and Negative Syndrome Scale (PANSS).
27-1	4614-4623	Diagnosis	_
27-2	4624-4626	of	_
27-3	4627-4640	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
27-4	4641-4643	or	_
27-5	4644-4659	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
27-6	4660-4668	disorder	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
27-7	4669-4671	in	_
27-8	4672-4675	ESZ	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
27-9	4676-4684	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
27-10	4685-4688	was	_
27-11	4689-4697	verified	_
27-12	4698-4703	using	_
27-13	4704-4707	the	_
27-14	4708-4718	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
27-15	4719-4727	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
27-16	4728-4737	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
27-17	4738-4741	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
27-18	4742-4748	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
27-19	4749-4750	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
27-20	4751-4755	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
27-21	4756-4757	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
27-22	4758-4761	and	_
27-23	4762-4769	symptom	_
27-24	4770-4778	severity	_
27-25	4779-4782	was	_
27-26	4783-4791	assessed	_
27-27	4792-4797	using	_
27-28	4798-4801	the	_
27-29	4802-4810	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
27-30	4811-4814	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
27-31	4815-4823	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
27-32	4824-4832	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
27-33	4833-4838	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
27-34	4839-4840	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
27-35	4841-4846	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
27-36	4847-4848	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
27-37	4849-4850	.	_

Text=Most of the ESZ patients (53/58; 91%) were taking antipsychotic medication at the time of testing.
28-1	4851-4855	Most	_
28-2	4856-4858	of	_
28-3	4859-4862	the	_
28-4	4863-4866	ESZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
28-5	4867-4875	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
28-6	4876-4877	(	_
28-7	4878-4883	53/58	_
28-8	4884-4885	;	_
28-9	4886-4888	91	_
28-10	4889-4890	%	_
28-11	4891-4892	)	_
28-12	4893-4897	were	_
28-13	4898-4904	taking	_
28-14	4905-4918	antipsychotic	_
28-15	4919-4929	medication	_
28-16	4930-4932	at	_
28-17	4933-4936	the	_
28-18	4937-4941	time	_
28-19	4942-4944	of	_
28-20	4945-4952	testing	_
28-21	4953-4954	.	_

Text=HC subjects were recruited from the community and did not meet current or lifetime criteria for major Axis I psychiatric disorders based on the SCID.
29-1	4955-4957	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
29-2	4958-4966	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
29-3	4967-4971	were	_
29-4	4972-4981	recruited	_
29-5	4982-4986	from	_
29-6	4987-4990	the	_
29-7	4991-5000	community	_
29-8	5001-5004	and	_
29-9	5005-5008	did	_
29-10	5009-5012	not	_
29-11	5013-5017	meet	_
29-12	5018-5025	current	_
29-13	5026-5028	or	_
29-14	5029-5037	lifetime	_
29-15	5038-5046	criteria	_
29-16	5047-5050	for	_
29-17	5051-5056	major	_
29-18	5057-5061	Axis	_
29-19	5062-5063	I	_
29-20	5064-5075	psychiatric	_
29-21	5076-5085	disorders	_
29-22	5086-5091	based	_
29-23	5092-5094	on	_
29-24	5095-5098	the	_
29-25	5099-5103	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
29-26	5104-5105	.	_

Text=The same data were analyzed using dynamic connectivity analysis in our previous study.
30-1	5106-5109	The	_
30-2	5110-5114	same	_
30-3	5115-5119	data	_
30-4	5120-5124	were	_
30-5	5125-5133	analyzed	_
30-6	5134-5139	using	_
30-7	5140-5147	dynamic	_
30-8	5148-5160	connectivity	_
30-9	5161-5169	analysis	_
30-10	5170-5172	in	_
30-11	5173-5176	our	_
30-12	5177-5185	previous	_
30-13	5186-5191	study	_
30-14	5192-5193	.	_

Text=MRI scan acquisition All brain images were acquired on a 3 T Siemens TIM Trio scanner at the UCSF Neuroimaging Center.
31-1	5194-5197	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
31-2	5198-5202	scan	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
31-3	5203-5214	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
31-4	5215-5218	All	_
31-5	5219-5224	brain	_
31-6	5225-5231	images	_
31-7	5232-5236	were	_
31-8	5237-5245	acquired	_
31-9	5246-5248	on	_
31-10	5249-5250	a	_
31-11	5251-5252	3	http://maven.renci.org/NeuroBridge/neurobridge#2Level
31-12	5253-5254	T	http://maven.renci.org/NeuroBridge/neurobridge#2Level
31-13	5255-5262	Siemens	http://maven.renci.org/NeuroBridge/neurobridge#2Level
31-14	5263-5266	TIM	http://maven.renci.org/NeuroBridge/neurobridge#2Level
31-15	5267-5271	Trio	http://maven.renci.org/NeuroBridge/neurobridge#2Level
31-16	5272-5279	scanner	http://maven.renci.org/NeuroBridge/neurobridge#2Level
31-17	5280-5282	at	_
31-18	5283-5286	the	_
31-19	5287-5291	UCSF	_
31-20	5292-5304	Neuroimaging	_
31-21	5305-5311	Center	_
31-22	5312-5313	.	_

Text=Resting-state scans were acquired using whole-brain echo-planar imaging (EPI) sequences.
32-1	5314-5327	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
32-2	5328-5333	scans	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
32-3	5334-5338	were	_
32-4	5339-5347	acquired	_
32-5	5348-5353	using	_
32-6	5354-5365	whole-brain	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeBrainDisorder
32-7	5366-5377	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
32-8	5378-5385	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
32-9	5386-5387	(	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
32-10	5388-5391	EPI	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
32-11	5392-5393	)	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
32-12	5394-5403	sequences	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
32-13	5404-5405	.	_

Text=Rest scans lasted 6 min, during which 180 functional images were obtained (32 axial slices, 3.5 mm slice thickness, 1.05 mm inter-slice gap, TR = 2 s, TE = 29 ms, flip angle = 75°, FOV = 24 cm, 64 × 64 matrix).
33-1	5406-5410	Rest	_
33-2	5411-5416	scans	_
33-3	5417-5423	lasted	_
33-4	5424-5425	6	_
33-5	5426-5429	min	_
33-6	5430-5431	,	_
33-7	5432-5438	during	_
33-8	5439-5444	which	_
33-9	5445-5448	180	_
33-10	5449-5459	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
33-11	5460-5466	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
33-12	5467-5471	were	_
33-13	5472-5480	obtained	_
33-14	5481-5482	(	_
33-15	5483-5485	32	_
33-16	5486-5491	axial	_
33-17	5492-5498	slices	_
33-18	5499-5500	,	_
33-19	5501-5504	3.5	_
33-20	5505-5507	mm	_
33-21	5508-5513	slice	_
33-22	5514-5523	thickness	_
33-23	5524-5525	,	_
33-24	5526-5530	1.05	_
33-25	5531-5533	mm	_
33-26	5534-5545	inter-slice	_
33-27	5546-5549	gap	_
33-28	5550-5551	,	_
33-29	5552-5554	TR	_
33-30	5555-5556	=	_
33-31	5557-5558	2	_
33-32	5559-5560	s	_
33-33	5561-5562	,	_
33-34	5563-5565	TE	_
33-35	5566-5567	=	_
33-36	5568-5570	29	_
33-37	5571-5573	ms	_
33-38	5574-5575	,	_
33-39	5576-5580	flip	_
33-40	5581-5586	angle	_
33-41	5587-5588	=	_
33-42	5589-5592	75°	_
33-43	5593-5594	,	_
33-44	5595-5598	FOV	_
33-45	5599-5600	=	_
33-46	5601-5603	24	_
33-47	5604-5606	cm	_
33-48	5607-5608	,	_
33-49	5609-5611	64	_
33-50	5612-5613	×	_
33-51	5614-5616	64	_
33-52	5617-5623	matrix	_
33-53	5624-5625	)	_
33-54	5626-5627	.	_

Text=Subjects were instructed to rest with their eyes closed and to stay awake.
34-1	5628-5636	Subjects	_
34-2	5637-5641	were	_
34-3	5642-5652	instructed	_
34-4	5653-5655	to	_
34-5	5656-5660	rest	_
34-6	5661-5665	with	_
34-7	5666-5671	their	_
34-8	5672-5676	eyes	_
34-9	5677-5683	closed	_
34-10	5684-5687	and	_
34-11	5688-5690	to	_
34-12	5691-5695	stay	_
34-13	5696-5701	awake	_
34-14	5702-5703	.	_

Text=MRI data preprocessing FMRI data from each subject were preprocessed using Statistical Parametric Mapping (SPM8) (http: //www.fil.ion.ucl.ac.uk/spm).
35-1	5704-5707	MRI	_
35-2	5708-5712	data	_
35-3	5713-5726	preprocessing	_
35-4	5727-5731	FMRI	_
35-5	5732-5736	data	_
35-6	5737-5741	from	_
35-7	5742-5746	each	_
35-8	5747-5754	subject	_
35-9	5755-5759	were	_
35-10	5760-5772	preprocessed	_
35-11	5773-5778	using	_
35-12	5779-5790	Statistical	_
35-13	5791-5801	Parametric	_
35-14	5802-5809	Mapping	_
35-15	5810-5811	(	_
35-16	5812-5816	SPM8	_
35-17	5817-5818	)	_
35-18	5819-5820	(	_
35-19	5821-5825	http	_
35-20	5826-5827	:	_
35-21	5828-5855	//www.fil.ion.ucl.ac.uk/spm	_
35-22	5856-5857	)	_
35-23	5858-5859	.	_

Text=The first ten volumes were discarded to allow for T1 equilibration effects, and the remaining volumes in the run were then slice-time corrected and realigned to the first volume to correct for head motion.
36-1	5860-5863	The	_
36-2	5864-5869	first	_
36-3	5870-5873	ten	_
36-4	5874-5881	volumes	_
36-5	5882-5886	were	_
36-6	5887-5896	discarded	_
36-7	5897-5899	to	_
36-8	5900-5905	allow	_
36-9	5906-5909	for	_
36-10	5910-5912	T1	_
36-11	5913-5926	equilibration	_
36-12	5927-5934	effects	_
36-13	5935-5936	,	_
36-14	5937-5940	and	_
36-15	5941-5944	the	_
36-16	5945-5954	remaining	_
36-17	5955-5962	volumes	_
36-18	5963-5965	in	_
36-19	5966-5969	the	_
36-20	5970-5973	run	_
36-21	5974-5978	were	_
36-22	5979-5983	then	_
36-23	5984-5994	slice-time	_
36-24	5995-6004	corrected	_
36-25	6005-6008	and	_
36-26	6009-6018	realigned	_
36-27	6019-6021	to	_
36-28	6022-6025	the	_
36-29	6026-6031	first	_
36-30	6032-6038	volume	_
36-31	6039-6041	to	_
36-32	6042-6049	correct	_
36-33	6050-6053	for	_
36-34	6054-6058	head	_
36-35	6059-6065	motion	_
36-36	6066-6067	.	_

Text=In terms of head motion, translations were <4 mm and rotations did not exceed 4° in all axes over the entire fMRI run for all included subjects.
37-1	6068-6070	In	_
37-2	6071-6076	terms	_
37-3	6077-6079	of	_
37-4	6080-6084	head	_
37-5	6085-6091	motion	_
37-6	6092-6093	,	_
37-7	6094-6106	translations	_
37-8	6107-6111	were	_
37-9	6112-6113	<	_
37-10	6114-6115	4	_
37-11	6116-6118	mm	_
37-12	6119-6122	and	_
37-13	6123-6132	rotations	_
37-14	6133-6136	did	_
37-15	6137-6140	not	_
37-16	6141-6147	exceed	_
37-17	6148-6150	4°	_
37-18	6151-6153	in	_
37-19	6154-6157	all	_
37-20	6158-6162	axes	_
37-21	6163-6167	over	_
37-22	6168-6171	the	_
37-23	6172-6178	entire	_
37-24	6179-6183	fMRI	_
37-25	6184-6187	run	_
37-26	6188-6191	for	_
37-27	6192-6195	all	_
37-28	6196-6204	included	_
37-29	6205-6213	subjects	_
37-30	6214-6215	.	_

Text=There were no significant group differences (p> 0.05, tested by analysis of variance) in the motion parameters displayed in Table 1.
38-1	6216-6221	There	_
38-2	6222-6226	were	_
38-3	6227-6229	no	_
38-4	6230-6241	significant	_
38-5	6242-6247	group	_
38-6	6248-6259	differences	_
38-7	6260-6261	(	_
38-8	6262-6263	p	_
38-9	6264-6265	>	_
38-10	6266-6270	0.05	_
38-11	6271-6272	,	_
38-12	6273-6279	tested	_
38-13	6280-6282	by	_
38-14	6283-6291	analysis	_
38-15	6292-6294	of	_
38-16	6295-6303	variance	_
38-17	6304-6305	)	_
38-18	6306-6308	in	_
38-19	6309-6312	the	_
38-20	6313-6319	motion	_
38-21	6320-6330	parameters	_
38-22	6331-6340	displayed	_
38-23	6341-6343	in	_
38-24	6344-6349	Table	_
38-25	6350-6351	1	_
38-26	6352-6353	.	_

Text=Subsequently, the images were spatially normalized to the Montreal Neurological Institute (MNI) EPI template, resliced to 3 mm × 3 mm × 3 mm voxels, and smoothed with a Gaussian kernel with a full-width at half-maximum (FWHM) of 6 mm.
39-1	6354-6366	Subsequently	_
39-2	6367-6368	,	_
39-3	6369-6372	the	_
39-4	6373-6379	images	_
39-5	6380-6384	were	_
39-6	6385-6394	spatially	_
39-7	6395-6405	normalized	_
39-8	6406-6408	to	_
39-9	6409-6412	the	_
39-10	6413-6421	Montreal	_
39-11	6422-6434	Neurological	_
39-12	6435-6444	Institute	_
39-13	6445-6446	(	_
39-14	6447-6450	MNI	_
39-15	6451-6452	)	_
39-16	6453-6456	EPI	_
39-17	6457-6465	template	_
39-18	6466-6467	,	_
39-19	6468-6476	resliced	_
39-20	6477-6479	to	_
39-21	6480-6481	3	_
39-22	6482-6484	mm	_
39-23	6485-6486	×	_
39-24	6487-6488	3	_
39-25	6489-6491	mm	_
39-26	6492-6493	×	_
39-27	6494-6495	3	_
39-28	6496-6498	mm	_
39-29	6499-6505	voxels	_
39-30	6506-6507	,	_
39-31	6508-6511	and	_
39-32	6512-6520	smoothed	_
39-33	6521-6525	with	_
39-34	6526-6527	a	_
39-35	6528-6536	Gaussian	_
39-36	6537-6543	kernel	_
39-37	6544-6548	with	_
39-38	6549-6550	a	_
39-39	6551-6561	full-width	_
39-40	6562-6564	at	_
39-41	6565-6577	half-maximum	_
39-42	6578-6579	(	_
39-43	6580-6584	FWHM	_
39-44	6585-6586	)	_
39-45	6587-6589	of	_
39-46	6590-6591	6	_
39-47	6592-6594	mm	_
39-48	6595-6596	.	_

Text=Estimating intrinsic functional networks using GIG-ICA We applied GIG-ICA to the preprocessed fMRI data of all subjects to estimate each subject's INs, resulting in INs with correspondence across subjects while also retaining subject-specific network features.
40-1	6597-6607	Estimating	_
40-2	6608-6617	intrinsic	_
40-3	6618-6628	functional	_
40-4	6629-6637	networks	_
40-5	6638-6643	using	_
40-6	6644-6651	GIG-ICA	_
40-7	6652-6654	We	_
40-8	6655-6662	applied	_
40-9	6663-6670	GIG-ICA	_
40-10	6671-6673	to	_
40-11	6674-6677	the	_
40-12	6678-6690	preprocessed	_
40-13	6691-6695	fMRI	_
40-14	6696-6700	data	_
40-15	6701-6703	of	_
40-16	6704-6707	all	_
40-17	6708-6716	subjects	_
40-18	6717-6719	to	_
40-19	6720-6728	estimate	_
40-20	6729-6733	each	_
40-21	6734-6741	subject	_
40-22	6742-6744	's	_
40-23	6745-6748	INs	_
40-24	6749-6750	,	_
40-25	6751-6760	resulting	_
40-26	6761-6763	in	_
40-27	6764-6767	INs	_
40-28	6768-6772	with	_
40-29	6773-6787	correspondence	_
40-30	6788-6794	across	_
40-31	6795-6803	subjects	_
40-32	6804-6809	while	_
40-33	6810-6814	also	_
40-34	6815-6824	retaining	_
40-35	6825-6841	subject-specific	_
40-36	6842-6849	network	_
40-37	6850-6858	features	_
40-38	6859-6860	.	_

Text=Our method primarily involved the following three steps.
41-1	6861-6864	Our	_
41-2	6865-6871	method	_
41-3	6872-6881	primarily	_
41-4	6882-6890	involved	_
41-5	6891-6894	the	_
41-6	6895-6904	following	_
41-7	6905-6910	three	_
41-8	6911-6916	steps	_
41-9	6917-6918	.	_

Text=First, based on the temporally-concatenated fMRI data of 181 subjects, ICA with the Infomax algorithm was used to estimate the group-level ICs.
42-1	6919-6924	First	_
42-2	6925-6926	,	_
42-3	6927-6932	based	_
42-4	6933-6935	on	_
42-5	6936-6939	the	_
42-6	6940-6963	temporally-concatenated	_
42-7	6964-6968	fMRI	_
42-8	6969-6973	data	_
42-9	6974-6976	of	_
42-10	6977-6980	181	_
42-11	6981-6989	subjects	_
42-12	6990-6991	,	_
42-13	6992-6995	ICA	_
42-14	6996-7000	with	_
42-15	7001-7004	the	_
42-16	7005-7012	Infomax	_
42-17	7013-7022	algorithm	_
42-18	7023-7026	was	_
42-19	7027-7031	used	_
42-20	7032-7034	to	_
42-21	7035-7043	estimate	_
42-22	7044-7047	the	_
42-23	7048-7059	group-level	_
42-24	7060-7063	ICs	_
42-25	7064-7065	.	_

Text=In order to decrease the influence of random initializations, we performed ICASSO with 20 ICA runs followed by selection of the most reliable ICA run to obtain reliable group-level ICs.
43-1	7066-7068	In	_
43-2	7069-7074	order	_
43-3	7075-7077	to	_
43-4	7078-7086	decrease	_
43-5	7087-7090	the	_
43-6	7091-7100	influence	_
43-7	7101-7103	of	_
43-8	7104-7110	random	_
43-9	7111-7126	initializations	_
43-10	7127-7128	,	_
43-11	7129-7131	we	_
43-12	7132-7141	performed	_
43-13	7142-7148	ICASSO	_
43-14	7149-7153	with	_
43-15	7154-7156	20	_
43-16	7157-7160	ICA	_
43-17	7161-7165	runs	_
43-18	7166-7174	followed	_
43-19	7175-7177	by	_
43-20	7178-7187	selection	_
43-21	7188-7190	of	_
43-22	7191-7194	the	_
43-23	7195-7199	most	_
43-24	7200-7208	reliable	_
43-25	7209-7212	ICA	_
43-26	7213-7216	run	_
43-27	7217-7219	to	_
43-28	7220-7226	obtain	_
43-29	7227-7235	reliable	_
43-30	7236-7247	group-level	_
43-31	7248-7251	ICs	_
43-32	7252-7253	.	_

Text=Before the group-level ICA, subject-level and group-level PCAs were applied to reduce the dimensionality of the fMRI data.
44-1	7254-7260	Before	_
44-2	7261-7264	the	_
44-3	7265-7276	group-level	_
44-4	7277-7280	ICA	_
44-5	7281-7282	,	_
44-6	7283-7296	subject-level	_
44-7	7297-7300	and	_
44-8	7301-7312	group-level	_
44-9	7313-7317	PCAs	_
44-10	7318-7322	were	_
44-11	7323-7330	applied	_
44-12	7331-7333	to	_
44-13	7334-7340	reduce	_
44-14	7341-7344	the	_
44-15	7345-7359	dimensionality	_
44-16	7360-7362	of	_
44-17	7363-7366	the	_
44-18	7367-7371	fMRI	_
44-19	7372-7376	data	_
44-20	7377-7378	.	_

Text=In this study, the number of ICs was set to 30 based on previous work, and the number of principle components used in the subject-level PCAs was specified as a greater number (i.e., 60) as recommended.
45-1	7379-7381	In	_
45-2	7382-7386	this	_
45-3	7387-7392	study	_
45-4	7393-7394	,	_
45-5	7395-7398	the	_
45-6	7399-7405	number	_
45-7	7406-7408	of	_
45-8	7409-7412	ICs	_
45-9	7413-7416	was	_
45-10	7417-7420	set	_
45-11	7421-7423	to	_
45-12	7424-7426	30	_
45-13	7427-7432	based	_
45-14	7433-7435	on	_
45-15	7436-7444	previous	_
45-16	7445-7449	work	_
45-17	7450-7451	,	_
45-18	7452-7455	and	_
45-19	7456-7459	the	_
45-20	7460-7466	number	_
45-21	7467-7469	of	_
45-22	7470-7479	principle	_
45-23	7480-7490	components	_
45-24	7491-7495	used	_
45-25	7496-7498	in	_
45-26	7499-7502	the	_
45-27	7503-7516	subject-level	_
45-28	7517-7521	PCAs	_
45-29	7522-7525	was	_
45-30	7526-7535	specified	_
45-31	7536-7538	as	_
45-32	7539-7540	a	_
45-33	7541-7548	greater	_
45-34	7549-7555	number	_
45-35	7556-7557	(	_
45-36	7558-7562	i.e.	_
45-37	7563-7564	,	_
45-38	7565-7567	60	_
45-39	7568-7569	)	_
45-40	7570-7572	as	_
45-41	7573-7584	recommended	_
45-42	7585-7586	.	_

Text=Thus, 30 group -level ICs were obtained and Z-scored.
46-1	7587-7591	Thus	_
46-2	7592-7593	,	_
46-3	7594-7596	30	_
46-4	7597-7602	group	_
46-5	7603-7609	-level	_
46-6	7610-7613	ICs	_
46-7	7614-7618	were	_
46-8	7619-7627	obtained	_
46-9	7628-7631	and	_
46-10	7632-7640	Z-scored	_
46-11	7641-7642	.	_

Text=It is worth noting that the sign of each resulting group-level IC is arbitrary.
47-1	7643-7645	It	_
47-2	7646-7648	is	_
47-3	7649-7654	worth	_
47-4	7655-7661	noting	_
47-5	7662-7666	that	_
47-6	7667-7670	the	_
47-7	7671-7675	sign	_
47-8	7676-7678	of	_
47-9	7679-7683	each	_
47-10	7684-7693	resulting	_
47-11	7694-7705	group-level	_
47-12	7706-7708	IC	_
47-13	7709-7711	is	_
47-14	7712-7721	arbitrary	_
47-15	7722-7723	.	_

Text=In our study, we computed the skewness of each IC and flipped the IC if its skewness was negative.
48-1	7724-7726	In	_
48-2	7727-7730	our	_
48-3	7731-7736	study	_
48-4	7737-7738	,	_
48-5	7739-7741	we	_
48-6	7742-7750	computed	_
48-7	7751-7754	the	_
48-8	7755-7763	skewness	_
48-9	7764-7766	of	_
48-10	7767-7771	each	_
48-11	7772-7774	IC	_
48-12	7775-7778	and	_
48-13	7779-7786	flipped	_
48-14	7787-7790	the	_
48-15	7791-7793	IC	_
48-16	7794-7796	if	_
48-17	7797-7800	its	_
48-18	7801-7809	skewness	_
48-19	7810-7813	was	_
48-20	7814-7822	negative	_
48-21	7823-7824	.	_

Text=Consequently, the positive Z-scores in each IC represented the voxels contributing the most to the associated network.
49-1	7825-7837	Consequently	_
49-2	7838-7839	,	_
49-3	7840-7843	the	_
49-4	7844-7852	positive	_
49-5	7853-7861	Z-scores	_
49-6	7862-7864	in	_
49-7	7865-7869	each	_
49-8	7870-7872	IC	_
49-9	7873-7884	represented	_
49-10	7885-7888	the	_
49-11	7889-7895	voxels	_
49-12	7896-7908	contributing	_
49-13	7909-7912	the	_
49-14	7913-7917	most	_
49-15	7918-7920	to	_
49-16	7921-7924	the	_
49-17	7925-7935	associated	_
49-18	7936-7943	network	_
49-19	7944-7945	.	_

Text=Second, we manually identified the meaningful group-level networks after carefully inspecting all group-level ICs' spatial maps.
50-1	7946-7952	Second	_
50-2	7953-7954	,	_
50-3	7955-7957	we	_
50-4	7958-7966	manually	_
50-5	7967-7977	identified	_
50-6	7978-7981	the	_
50-7	7982-7992	meaningful	_
50-8	7993-8004	group-level	_
50-9	8005-8013	networks	_
50-10	8014-8019	after	_
50-11	8020-8029	carefully	_
50-12	8030-8040	inspecting	_
50-13	8041-8044	all	_
50-14	8045-8056	group-level	_
50-15	8057-8060	ICs	_
50-16	8061-8062	'	_
50-17	8063-8070	spatial	_
50-18	8071-8075	maps	_
50-19	8076-8077	.	_

Text=If the primary activation of one IC's spatial map is located in gray matter, smooth and continuous, we preferred to regard it as an interesting functional network.
51-1	8078-8080	If	_
51-2	8081-8084	the	_
51-3	8085-8092	primary	_
51-4	8093-8103	activation	_
51-5	8104-8106	of	_
51-6	8107-8110	one	_
51-7	8111-8113	IC	_
51-8	8114-8116	's	_
51-9	8117-8124	spatial	_
51-10	8125-8128	map	_
51-11	8129-8131	is	_
51-12	8132-8139	located	_
51-13	8140-8142	in	_
51-14	8143-8147	gray	_
51-15	8148-8154	matter	_
51-16	8155-8156	,	_
51-17	8157-8163	smooth	_
51-18	8164-8167	and	_
51-19	8168-8178	continuous	_
51-20	8179-8180	,	_
51-21	8181-8183	we	_
51-22	8184-8193	preferred	_
51-23	8194-8196	to	_
51-24	8197-8203	regard	_
51-25	8204-8206	it	_
51-26	8207-8209	as	_
51-27	8210-8212	an	_
51-28	8213-8224	interesting	_
51-29	8225-8235	functional	_
51-30	8236-8243	network	_
51-31	8244-8245	.	_

Text=Also, we referred to networks reported in previous studies to further confirm.
52-1	8246-8250	Also	_
52-2	8251-8252	,	_
52-3	8253-8255	we	_
52-4	8256-8264	referred	_
52-5	8265-8267	to	_
52-6	8268-8276	networks	_
52-7	8277-8285	reported	_
52-8	8286-8288	in	_
52-9	8289-8297	previous	_
52-10	8298-8305	studies	_
52-11	8306-8308	to	_
52-12	8309-8316	further	_
52-13	8317-8324	confirm	_
52-14	8325-8326	.	_

Text=The removed noise-related group-level ICs reflected head motion, physiological noise, and influence of scanner.
53-1	8327-8330	The	_
53-2	8331-8338	removed	_
53-3	8339-8352	noise-related	_
53-4	8353-8364	group-level	_
53-5	8365-8368	ICs	_
53-6	8369-8378	reflected	_
53-7	8379-8383	head	_
53-8	8384-8390	motion	_
53-9	8391-8392	,	_
53-10	8393-8406	physiological	_
53-11	8407-8412	noise	_
53-12	8413-8414	,	_
53-13	8415-8418	and	_
53-14	8419-8428	influence	_
53-15	8429-8431	of	_
53-16	8432-8439	scanner	_
53-17	8440-8441	.	_

Text=Third, the remaining meaningful group-level ICs were characterized as the group-level INs and then used to calculate the subject-specific INs based on a multi-objective function optimization algorithm.
54-1	8442-8447	Third	_
54-2	8448-8449	,	_
54-3	8450-8453	the	_
54-4	8454-8463	remaining	_
54-5	8464-8474	meaningful	_
54-6	8475-8486	group-level	_
54-7	8487-8490	ICs	_
54-8	8491-8495	were	_
54-9	8496-8509	characterized	_
54-10	8510-8512	as	_
54-11	8513-8516	the	_
54-12	8517-8528	group-level	_
54-13	8529-8532	INs	_
54-14	8533-8536	and	_
54-15	8537-8541	then	_
54-16	8542-8546	used	_
54-17	8547-8549	to	_
54-18	8550-8559	calculate	_
54-19	8560-8563	the	_
54-20	8564-8580	subject-specific	_
54-21	8581-8584	INs	_
54-22	8585-8590	based	_
54-23	8591-8593	on	_
54-24	8594-8595	a	_
54-25	8596-8611	multi-objective	_
54-26	8612-8620	function	_
54-27	8621-8633	optimization	_
54-28	8634-8643	algorithm	_
54-29	8644-8645	.	_

Text=GIG-ICA automatically yields Z-scored the subject-specific INs.
55-1	8646-8653	GIG-ICA	_
55-2	8654-8667	automatically	_
55-3	8668-8674	yields	_
55-4	8675-8683	Z-scored	_
55-5	8684-8687	the	_
55-6	8688-8704	subject-specific	_
55-7	8705-8708	INs	_
55-8	8709-8710	.	_

Text=Finally, a regression model was utilized to estimate the corresponding time courses (reflecting fluctuations) of the individual INs for each subject's fMRI data.
56-1	8711-8718	Finally	_
56-2	8719-8720	,	_
56-3	8721-8722	a	_
56-4	8723-8733	regression	_
56-5	8734-8739	model	_
56-6	8740-8743	was	_
56-7	8744-8752	utilized	_
56-8	8753-8755	to	_
56-9	8756-8764	estimate	_
56-10	8765-8768	the	_
56-11	8769-8782	corresponding	_
56-12	8783-8787	time	_
56-13	8788-8795	courses	_
56-14	8796-8797	(	_
56-15	8798-8808	reflecting	_
56-16	8809-8821	fluctuations	_
56-17	8822-8823	)	_
56-18	8824-8826	of	_
56-19	8827-8830	the	_
56-20	8831-8841	individual	_
56-21	8842-8845	INs	_
56-22	8846-8849	for	_
56-23	8850-8854	each	_
56-24	8855-8862	subject	_
56-25	8863-8865	's	_
56-26	8866-8870	fMRI	_
56-27	8871-8875	data	_
56-28	8876-8877	.	_

Text=It is known that for each voxel in a given individual IN, a positive Z-score indicates that the time series (after preprocessing) in the voxel has a positive correlation with the time course of the IN; in contrast a negative Z-score represents that the time series in the voxel has a negative correlation with the time course of the IN.
57-1	8878-8880	It	_
57-2	8881-8883	is	_
57-3	8884-8889	known	_
57-4	8890-8894	that	_
57-5	8895-8898	for	_
57-6	8899-8903	each	_
57-7	8904-8909	voxel	_
57-8	8910-8912	in	_
57-9	8913-8914	a	_
57-10	8915-8920	given	_
57-11	8921-8931	individual	_
57-12	8932-8934	IN	_
57-13	8935-8936	,	_
57-14	8937-8938	a	_
57-15	8939-8947	positive	_
57-16	8948-8955	Z-score	_
57-17	8956-8965	indicates	_
57-18	8966-8970	that	_
57-19	8971-8974	the	_
57-20	8975-8979	time	_
57-21	8980-8986	series	_
57-22	8987-8988	(	_
57-23	8989-8994	after	_
57-24	8995-9008	preprocessing	_
57-25	9009-9010	)	_
57-26	9011-9013	in	_
57-27	9014-9017	the	_
57-28	9018-9023	voxel	_
57-29	9024-9027	has	_
57-30	9028-9029	a	_
57-31	9030-9038	positive	_
57-32	9039-9050	correlation	_
57-33	9051-9055	with	_
57-34	9056-9059	the	_
57-35	9060-9064	time	_
57-36	9065-9071	course	_
57-37	9072-9074	of	_
57-38	9075-9078	the	_
57-39	9079-9081	IN	_
57-40	9082-9083	;	_
57-41	9084-9086	in	_
57-42	9087-9095	contrast	_
57-43	9096-9097	a	_
57-44	9098-9106	negative	_
57-45	9107-9114	Z-score	_
57-46	9115-9125	represents	_
57-47	9126-9130	that	_
57-48	9131-9134	the	_
57-49	9135-9139	time	_
57-50	9140-9146	series	_
57-51	9147-9149	in	_
57-52	9150-9153	the	_
57-53	9154-9159	voxel	_
57-54	9160-9163	has	_
57-55	9164-9165	a	_
57-56	9166-9174	negative	_
57-57	9175-9186	correlation	_
57-58	9187-9191	with	_
57-59	9192-9195	the	_
57-60	9196-9200	time	_
57-61	9201-9207	course	_
57-62	9208-9210	of	_
57-63	9211-9214	the	_
57-64	9215-9217	IN	_
57-65	9218-9219	.	_

Text=Therefore, for one specific IN, a region containing voxels with high positive Z-scores (taking a region only including two voxels as an example, Z-scores of two voxels = 10 and 9) tends to have stronger co-activation (i.e., positive correlation) within the IN compared to a region containing voxels with low positive Z-scores (e.g., Z-scores of two voxels = 2 and 1).
58-1	9220-9229	Therefore	_
58-2	9230-9231	,	_
58-3	9232-9235	for	_
58-4	9236-9239	one	_
58-5	9240-9248	specific	_
58-6	9249-9251	IN	_
58-7	9252-9253	,	_
58-8	9254-9255	a	_
58-9	9256-9262	region	_
58-10	9263-9273	containing	_
58-11	9274-9280	voxels	_
58-12	9281-9285	with	_
58-13	9286-9290	high	_
58-14	9291-9299	positive	_
58-15	9300-9308	Z-scores	_
58-16	9309-9310	(	_
58-17	9311-9317	taking	_
58-18	9318-9319	a	_
58-19	9320-9326	region	_
58-20	9327-9331	only	_
58-21	9332-9341	including	_
58-22	9342-9345	two	_
58-23	9346-9352	voxels	_
58-24	9353-9355	as	_
58-25	9356-9358	an	_
58-26	9359-9366	example	_
58-27	9367-9368	,	_
58-28	9369-9377	Z-scores	_
58-29	9378-9380	of	_
58-30	9381-9384	two	_
58-31	9385-9391	voxels	_
58-32	9392-9393	=	_
58-33	9394-9396	10	_
58-34	9397-9400	and	_
58-35	9401-9402	9	_
58-36	9403-9404	)	_
58-37	9405-9410	tends	_
58-38	9411-9413	to	_
58-39	9414-9418	have	_
58-40	9419-9427	stronger	_
58-41	9428-9441	co-activation	_
58-42	9442-9443	(	_
58-43	9444-9448	i.e.	_
58-44	9449-9450	,	_
58-45	9451-9459	positive	_
58-46	9460-9471	correlation	_
58-47	9472-9473	)	_
58-48	9474-9480	within	_
58-49	9481-9484	the	_
58-50	9485-9487	IN	_
58-51	9488-9496	compared	_
58-52	9497-9499	to	_
58-53	9500-9501	a	_
58-54	9502-9508	region	_
58-55	9509-9519	containing	_
58-56	9520-9526	voxels	_
58-57	9527-9531	with	_
58-58	9532-9535	low	_
58-59	9536-9544	positive	_
58-60	9545-9553	Z-scores	_
58-61	9554-9555	(	_
58-62	9556-9560	e.g.	_
58-63	9561-9562	,	_
58-64	9563-9571	Z-scores	_
58-65	9572-9574	of	_
58-66	9575-9578	two	_
58-67	9579-9585	voxels	_
58-68	9586-9587	=	_
58-69	9588-9589	2	_
58-70	9590-9593	and	_
58-71	9594-9595	1	_
58-72	9596-9597	)	_
58-73	9598-9599	.	_

Text=In such case, the mean of the Z-scores in one region can reflect the co-activation extent of the region.
59-1	9600-9602	In	_
59-2	9603-9607	such	_
59-3	9608-9612	case	_
59-4	9613-9614	,	_
59-5	9615-9618	the	_
59-6	9619-9623	mean	_
59-7	9624-9626	of	_
59-8	9627-9630	the	_
59-9	9631-9639	Z-scores	_
59-10	9640-9642	in	_
59-11	9643-9646	one	_
59-12	9647-9653	region	_
59-13	9654-9657	can	_
59-14	9658-9665	reflect	_
59-15	9666-9669	the	_
59-16	9670-9683	co-activation	_
59-17	9684-9690	extent	_
59-18	9691-9693	of	_
59-19	9694-9697	the	_
59-20	9698-9704	region	_
59-21	9705-9706	.	_

Text=In fact, if a region contains voxels with greater negative Z-scores (e.g., Z-scores of two voxels = − 10 and − 9) relative to the other region (e.g., Z-scores of two voxels = − 2 and − 1), the former also tends to have stronger co-activation than the later.
60-1	9707-9709	In	_
60-2	9710-9714	fact	_
60-3	9715-9716	,	_
60-4	9717-9719	if	_
60-5	9720-9721	a	_
60-6	9722-9728	region	_
60-7	9729-9737	contains	_
60-8	9738-9744	voxels	_
60-9	9745-9749	with	_
60-10	9750-9757	greater	_
60-11	9758-9766	negative	_
60-12	9767-9775	Z-scores	_
60-13	9776-9777	(	_
60-14	9778-9782	e.g.	_
60-15	9783-9784	,	_
60-16	9785-9793	Z-scores	_
60-17	9794-9796	of	_
60-18	9797-9800	two	_
60-19	9801-9807	voxels	_
60-20	9808-9809	=	_
60-21	9810-9811	−	_
60-22	9812-9814	10	_
60-23	9815-9818	and	_
60-24	9819-9820	−	_
60-25	9821-9822	9	_
60-26	9823-9824	)	_
60-27	9825-9833	relative	_
60-28	9834-9836	to	_
60-29	9837-9840	the	_
60-30	9841-9846	other	_
60-31	9847-9853	region	_
60-32	9854-9855	(	_
60-33	9856-9860	e.g.	_
60-34	9861-9862	,	_
60-35	9863-9871	Z-scores	_
60-36	9872-9874	of	_
60-37	9875-9878	two	_
60-38	9879-9885	voxels	_
60-39	9886-9887	=	_
60-40	9888-9889	−	_
60-41	9890-9891	2	_
60-42	9892-9895	and	_
60-43	9896-9897	−	_
60-44	9898-9899	1	_
60-45	9900-9901	)	_
60-46	9902-9903	,	_
60-47	9904-9907	the	_
60-48	9908-9914	former	_
60-49	9915-9919	also	_
60-50	9920-9925	tends	_
60-51	9926-9928	to	_
60-52	9929-9933	have	_
60-53	9934-9942	stronger	_
60-54	9943-9956	co-activation	_
60-55	9957-9961	than	_
60-56	9962-9965	the	_
60-57	9966-9971	later	_
60-58	9972-9973	.	_

Text=In this study, considering that the positive Z-scores contributing the most include important spatial maps in each IN, we focused on investigating group differences in voxels primarily associated with positive Z-scores to simplify the subsequent analyses.
61-1	9974-9976	In	_
61-2	9977-9981	this	_
61-3	9982-9987	study	_
61-4	9988-9989	,	_
61-5	9990-10001	considering	_
61-6	10002-10006	that	_
61-7	10007-10010	the	_
61-8	10011-10019	positive	_
61-9	10020-10028	Z-scores	_
61-10	10029-10041	contributing	_
61-11	10042-10045	the	_
61-12	10046-10050	most	_
61-13	10051-10058	include	_
61-14	10059-10068	important	_
61-15	10069-10076	spatial	_
61-16	10077-10081	maps	_
61-17	10082-10084	in	_
61-18	10085-10089	each	_
61-19	10090-10092	IN	_
61-20	10093-10094	,	_
61-21	10095-10097	we	_
61-22	10098-10105	focused	_
61-23	10106-10108	on	_
61-24	10109-10122	investigating	_
61-25	10123-10128	group	_
61-26	10129-10140	differences	_
61-27	10141-10143	in	_
61-28	10144-10150	voxels	_
61-29	10151-10160	primarily	_
61-30	10161-10171	associated	_
61-31	10172-10176	with	_
61-32	10177-10185	positive	_
61-33	10186-10194	Z-scores	_
61-34	10195-10197	to	_
61-35	10198-10206	simplify	_
61-36	10207-10210	the	_
61-37	10211-10221	subsequent	_
61-38	10222-10230	analyses	_
61-39	10231-10232	.	_

Text=It is also worth pointing out that if one region includes both higher and lower positive Z-scores (e.g., Z-scores of two voxels = 10 and 1) compared to the other region (e.g., Z-scores of two voxels = 2 and 8), we cannot determine which region has greater co-activation using Z-scores.
62-1	10233-10235	It	_
62-2	10236-10238	is	_
62-3	10239-10243	also	_
62-4	10244-10249	worth	_
62-5	10250-10258	pointing	_
62-6	10259-10262	out	_
62-7	10263-10267	that	_
62-8	10268-10270	if	_
62-9	10271-10274	one	_
62-10	10275-10281	region	_
62-11	10282-10290	includes	_
62-12	10291-10295	both	_
62-13	10296-10302	higher	_
62-14	10303-10306	and	_
62-15	10307-10312	lower	_
62-16	10313-10321	positive	_
62-17	10322-10330	Z-scores	_
62-18	10331-10332	(	_
62-19	10333-10337	e.g.	_
62-20	10338-10339	,	_
62-21	10340-10348	Z-scores	_
62-22	10349-10351	of	_
62-23	10352-10355	two	_
62-24	10356-10362	voxels	_
62-25	10363-10364	=	_
62-26	10365-10367	10	_
62-27	10368-10371	and	_
62-28	10372-10373	1	_
62-29	10374-10375	)	_
62-30	10376-10384	compared	_
62-31	10385-10387	to	_
62-32	10388-10391	the	_
62-33	10392-10397	other	_
62-34	10398-10404	region	_
62-35	10405-10406	(	_
62-36	10407-10411	e.g.	_
62-37	10412-10413	,	_
62-38	10414-10422	Z-scores	_
62-39	10423-10425	of	_
62-40	10426-10429	two	_
62-41	10430-10436	voxels	_
62-42	10437-10438	=	_
62-43	10439-10440	2	_
62-44	10441-10444	and	_
62-45	10445-10446	8	_
62-46	10447-10448	)	_
62-47	10449-10450	,	_
62-48	10451-10453	we	_
62-49	10454-10457	can	_
62-50	10458-10461	not	_
62-51	10462-10471	determine	_
62-52	10472-10477	which	_
62-53	10478-10484	region	_
62-54	10485-10488	has	_
62-55	10489-10496	greater	_
62-56	10497-10510	co-activation	_
62-57	10511-10516	using	_
62-58	10517-10525	Z-scores	_
62-59	10526-10527	.	_

Text=Therefore, in this work, we applied two-sample t-tests (rather than analysis of variance) to identify brain regions including voxels with consistent changing patterns between groups.
63-1	10528-10537	Therefore	_
63-2	10538-10539	,	_
63-3	10540-10542	in	_
63-4	10543-10547	this	_
63-5	10548-10552	work	_
63-6	10553-10554	,	_
63-7	10555-10557	we	_
63-8	10558-10565	applied	_
63-9	10566-10576	two-sample	_
63-10	10577-10584	t-tests	_
63-11	10585-10586	(	_
63-12	10587-10593	rather	_
63-13	10594-10598	than	_
63-14	10599-10607	analysis	_
63-15	10608-10610	of	_
63-16	10611-10619	variance	_
63-17	10620-10621	)	_
63-18	10622-10624	to	_
63-19	10625-10633	identify	_
63-20	10634-10639	brain	_
63-21	10640-10647	regions	_
63-22	10648-10657	including	_
63-23	10658-10664	voxels	_
63-24	10665-10669	with	_
63-25	10670-10680	consistent	_
63-26	10681-10689	changing	_
63-27	10690-10698	patterns	_
63-28	10699-10706	between	_
63-29	10707-10713	groups	_
63-30	10714-10715	.	_

Text=Identifying significant discriminative regions in intrinsic functional networks Based on the estimated subject-specific INs, we investigated differences in each corresponding IN across the three groups in order to examine the network abnormalities of the ESZ and CHR group relative to each other and to the HC group.
64-1	10716-10727	Identifying	_
64-2	10728-10739	significant	_
64-3	10740-10754	discriminative	_
64-4	10755-10762	regions	_
64-5	10763-10765	in	_
64-6	10766-10775	intrinsic	_
64-7	10776-10786	functional	_
64-8	10787-10795	networks	_
64-9	10796-10801	Based	_
64-10	10802-10804	on	_
64-11	10805-10808	the	_
64-12	10809-10818	estimated	_
64-13	10819-10835	subject-specific	_
64-14	10836-10839	INs	_
64-15	10840-10841	,	_
64-16	10842-10844	we	_
64-17	10845-10857	investigated	_
64-18	10858-10869	differences	_
64-19	10870-10872	in	_
64-20	10873-10877	each	_
64-21	10878-10891	corresponding	_
64-22	10892-10894	IN	_
64-23	10895-10901	across	_
64-24	10902-10905	the	_
64-25	10906-10911	three	_
64-26	10912-10918	groups	_
64-27	10919-10921	in	_
64-28	10922-10927	order	_
64-29	10928-10930	to	_
64-30	10931-10938	examine	_
64-31	10939-10942	the	_
64-32	10943-10950	network	_
64-33	10951-10964	abnormalities	_
64-34	10965-10967	of	_
64-35	10968-10971	the	_
64-36	10972-10975	ESZ	_
64-37	10976-10979	and	_
64-38	10980-10983	CHR	_
64-39	10984-10989	group	_
64-40	10990-10998	relative	_
64-41	10999-11001	to	_
64-42	11002-11006	each	_
64-43	11007-11012	other	_
64-44	11013-11016	and	_
64-45	11017-11019	to	_
64-46	11020-11023	the	_
64-47	11024-11026	HC	_
64-48	11027-11032	group	_
64-49	11033-11034	.	_

Text=For each IN, we performed three analysis steps that include (1) extracting important voxels positively contributing to the network (i.e., voxels primarily involving positive Z-scores) and generating a network mask, (2) identifying regions based on all possible 19 inter-group changing patterns in the network mask, and (3) investigating group differences in the co-activation of each significant discriminative region.
65-1	11035-11038	For	_
65-2	11039-11043	each	_
65-3	11044-11046	IN	_
65-4	11047-11048	,	_
65-5	11049-11051	we	_
65-6	11052-11061	performed	_
65-7	11062-11067	three	_
65-8	11068-11076	analysis	_
65-9	11077-11082	steps	_
65-10	11083-11087	that	_
65-11	11088-11095	include	_
65-12	11096-11097	(	_
65-13	11098-11099	1	_
65-14	11100-11101	)	_
65-15	11102-11112	extracting	_
65-16	11113-11122	important	_
65-17	11123-11129	voxels	_
65-18	11130-11140	positively	_
65-19	11141-11153	contributing	_
65-20	11154-11156	to	_
65-21	11157-11160	the	_
65-22	11161-11168	network	_
65-23	11169-11170	(	_
65-24	11171-11175	i.e.	_
65-25	11176-11177	,	_
65-26	11178-11184	voxels	_
65-27	11185-11194	primarily	_
65-28	11195-11204	involving	_
65-29	11205-11213	positive	_
65-30	11214-11222	Z-scores	_
65-31	11223-11224	)	_
65-32	11225-11228	and	_
65-33	11229-11239	generating	_
65-34	11240-11241	a	_
65-35	11242-11249	network	_
65-36	11250-11254	mask	_
65-37	11255-11256	,	_
65-38	11257-11258	(	_
65-39	11259-11260	2	_
65-40	11261-11262	)	_
65-41	11263-11274	identifying	_
65-42	11275-11282	regions	_
65-43	11283-11288	based	_
65-44	11289-11291	on	_
65-45	11292-11295	all	_
65-46	11296-11304	possible	_
65-47	11305-11307	19	_
65-48	11308-11319	inter-group	_
65-49	11320-11328	changing	_
65-50	11329-11337	patterns	_
65-51	11338-11340	in	_
65-52	11341-11344	the	_
65-53	11345-11352	network	_
65-54	11353-11357	mask	_
65-55	11358-11359	,	_
65-56	11360-11363	and	_
65-57	11364-11365	(	_
65-58	11366-11367	3	_
65-59	11368-11369	)	_
65-60	11370-11383	investigating	_
65-61	11384-11389	group	_
65-62	11390-11401	differences	_
65-63	11402-11404	in	_
65-64	11405-11408	the	_
65-65	11409-11422	co-activation	_
65-66	11423-11425	of	_
65-67	11426-11430	each	_
65-68	11431-11442	significant	_
65-69	11443-11457	discriminative	_
65-70	11458-11464	region	_
65-71	11465-11466	.	_

Text=We describe the detailed processing on each IC as follows.
66-1	11467-11469	We	_
66-2	11470-11478	describe	_
66-3	11479-11482	the	_
66-4	11483-11491	detailed	_
66-5	11492-11502	processing	_
66-6	11503-11505	on	_
66-7	11506-11510	each	_
66-8	11511-11513	IC	_
66-9	11514-11516	as	_
66-10	11517-11524	follows	_
66-11	11525-11526	.	_

Text=In the first step, for each voxel, a right-tailed one-sample t-test (p <0.01 with Bonferroni correction, i.e., p <0.01/the number of voxels in a brain mask = 0.01/69078 = 1.45e − 7) was applied to the voxel's Z-scores from the corresponding subject-specific INs of all 181 subjects to identify voxels whose Z-scores were positive in most of the subjects, resulting a network mask.
67-1	11527-11529	In	_
67-2	11530-11533	the	_
67-3	11534-11539	first	_
67-4	11540-11544	step	_
67-5	11545-11546	,	_
67-6	11547-11550	for	_
67-7	11551-11555	each	_
67-8	11556-11561	voxel	_
67-9	11562-11563	,	_
67-10	11564-11565	a	_
67-11	11566-11578	right-tailed	_
67-12	11579-11589	one-sample	_
67-13	11590-11596	t-test	_
67-14	11597-11598	(	_
67-15	11599-11600	p	_
67-16	11601-11602	<	_
67-17	11603-11607	0.01	_
67-18	11608-11612	with	_
67-19	11613-11623	Bonferroni	_
67-20	11624-11634	correction	_
67-21	11635-11636	,	_
67-22	11637-11641	i.e.	_
67-23	11642-11643	,	_
67-24	11644-11645	p	_
67-25	11646-11647	<	_
67-26	11648-11656	0.01/the	_
67-27	11657-11663	number	_
67-28	11664-11666	of	_
67-29	11667-11673	voxels	_
67-30	11674-11676	in	_
67-31	11677-11678	a	_
67-32	11679-11684	brain	_
67-33	11685-11689	mask	_
67-34	11690-11691	=	_
67-35	11692-11702	0.01/69078	_
67-36	11703-11704	=	_
67-37	11705-11710	1.45e	_
67-38	11711-11712	−	_
67-39	11713-11714	7	_
67-40	11715-11716	)	_
67-41	11717-11720	was	_
67-42	11721-11728	applied	_
67-43	11729-11731	to	_
67-44	11732-11735	the	_
67-45	11736-11741	voxel	_
67-46	11742-11744	's	_
67-47	11745-11753	Z-scores	_
67-48	11754-11758	from	_
67-49	11759-11762	the	_
67-50	11763-11776	corresponding	_
67-51	11777-11793	subject-specific	_
67-52	11794-11797	INs	_
67-53	11798-11800	of	_
67-54	11801-11804	all	_
67-55	11805-11808	181	_
67-56	11809-11817	subjects	_
67-57	11818-11820	to	_
67-58	11821-11829	identify	_
67-59	11830-11836	voxels	_
67-60	11837-11842	whose	_
67-61	11843-11851	Z-scores	_
67-62	11852-11856	were	_
67-63	11857-11865	positive	_
67-64	11866-11868	in	_
67-65	11869-11873	most	_
67-66	11874-11876	of	_
67-67	11877-11880	the	_
67-68	11881-11889	subjects	_
67-69	11890-11891	,	_
67-70	11892-11901	resulting	_
67-71	11902-11903	a	_
67-72	11904-11911	network	_
67-73	11912-11916	mask	_
67-74	11917-11918	.	_

Text=The subsequent second and third steps were performed on the voxels in the network mask.
68-1	11919-11922	The	_
68-2	11923-11933	subsequent	_
68-3	11934-11940	second	_
68-4	11941-11944	and	_
68-5	11945-11950	third	_
68-6	11951-11956	steps	_
68-7	11957-11961	were	_
68-8	11962-11971	performed	_
68-9	11972-11974	on	_
68-10	11975-11978	the	_
68-11	11979-11985	voxels	_
68-12	11986-11988	in	_
68-13	11989-11992	the	_
68-14	11993-12000	network	_
68-15	12001-12005	mask	_
68-16	12006-12007	.	_

Text=Additionally, we tested if our strategy may fail to find group differences in some important voxels (or regions) showing positive Z-scores in one group (e.g., HC) but not showing positive Z-scores in other groups (e.g., CHR and ESZ).
69-1	12008-12020	Additionally	_
69-2	12021-12022	,	_
69-3	12023-12025	we	_
69-4	12026-12032	tested	_
69-5	12033-12035	if	_
69-6	12036-12039	our	_
69-7	12040-12048	strategy	_
69-8	12049-12052	may	_
69-9	12053-12057	fail	_
69-10	12058-12060	to	_
69-11	12061-12065	find	_
69-12	12066-12071	group	_
69-13	12072-12083	differences	_
69-14	12084-12086	in	_
69-15	12087-12091	some	_
69-16	12092-12101	important	_
69-17	12102-12108	voxels	_
69-18	12109-12110	(	_
69-19	12111-12113	or	_
69-20	12114-12121	regions	_
69-21	12122-12123	)	_
69-22	12124-12131	showing	_
69-23	12132-12140	positive	_
69-24	12141-12149	Z-scores	_
69-25	12150-12152	in	_
69-26	12153-12156	one	_
69-27	12157-12162	group	_
69-28	12163-12164	(	_
69-29	12165-12169	e.g.	_
69-30	12170-12171	,	_
69-31	12172-12174	HC	_
69-32	12175-12176	)	_
69-33	12177-12180	but	_
69-34	12181-12184	not	_
69-35	12185-12192	showing	_
69-36	12193-12201	positive	_
69-37	12202-12210	Z-scores	_
69-38	12211-12213	in	_
69-39	12214-12219	other	_
69-40	12220-12226	groups	_
69-41	12227-12228	(	_
69-42	12229-12233	e.g.	_
69-43	12234-12235	,	_
69-44	12236-12239	CHR	_
69-45	12240-12243	and	_
69-46	12244-12247	ESZ	_
69-47	12248-12249	)	_
69-48	12250-12251	.	_

Text=So, we examined whether performing one-sample t-tests on each group separately may generate significantly different network masks compared to performing one-sample t-tests on all the three groups.
70-1	12252-12254	So	_
70-2	12255-12256	,	_
70-3	12257-12259	we	_
70-4	12260-12268	examined	_
70-5	12269-12276	whether	_
70-6	12277-12287	performing	_
70-7	12288-12298	one-sample	_
70-8	12299-12306	t-tests	_
70-9	12307-12309	on	_
70-10	12310-12314	each	_
70-11	12315-12320	group	_
70-12	12321-12331	separately	_
70-13	12332-12335	may	_
70-14	12336-12344	generate	_
70-15	12345-12358	significantly	_
70-16	12359-12368	different	_
70-17	12369-12376	network	_
70-18	12377-12382	masks	_
70-19	12383-12391	compared	_
70-20	12392-12394	to	_
70-21	12395-12405	performing	_
70-22	12406-12416	one-sample	_
70-23	12417-12424	t-tests	_
70-24	12425-12427	on	_
70-25	12428-12431	all	_
70-26	12432-12435	the	_
70-27	12436-12441	three	_
70-28	12442-12448	groups	_
70-29	12449-12450	.	_

Text=For each group (e.g., HC), voxel-wise right-tailed one-sample t-tests were applied on the corresponding individual-subject's networks.
71-1	12451-12454	For	_
71-2	12455-12459	each	_
71-3	12460-12465	group	_
71-4	12466-12467	(	_
71-5	12468-12472	e.g.	_
71-6	12473-12474	,	_
71-7	12475-12477	HC	_
71-8	12478-12479	)	_
71-9	12480-12481	,	_
71-10	12482-12492	voxel-wise	_
71-11	12493-12505	right-tailed	_
71-12	12506-12516	one-sample	_
71-13	12517-12524	t-tests	_
71-14	12525-12529	were	_
71-15	12530-12537	applied	_
71-16	12538-12540	on	_
71-17	12541-12544	the	_
71-18	12545-12558	corresponding	_
71-19	12559-12577	individual-subject	_
71-20	12578-12580	's	_
71-21	12581-12589	networks	_
71-22	12590-12591	.	_

Text=The parameter (p <0.01 with Bonferroni correction, i.e., p <0.01/the number of voxels in brain mask = 0.01/69078 = 1.45e − 7) used in one-sample t-tests on each group's subjects was as same as the parameter of one-sample t-tests on all subjects of three groups.
72-1	12592-12595	The	_
72-2	12596-12605	parameter	_
72-3	12606-12607	(	_
72-4	12608-12609	p	_
72-5	12610-12611	<	_
72-6	12612-12616	0.01	_
72-7	12617-12621	with	_
72-8	12622-12632	Bonferroni	_
72-9	12633-12643	correction	_
72-10	12644-12645	,	_
72-11	12646-12650	i.e.	_
72-12	12651-12652	,	_
72-13	12653-12654	p	_
72-14	12655-12656	<	_
72-15	12657-12665	0.01/the	_
72-16	12666-12672	number	_
72-17	12673-12675	of	_
72-18	12676-12682	voxels	_
72-19	12683-12685	in	_
72-20	12686-12691	brain	_
72-21	12692-12696	mask	_
72-22	12697-12698	=	_
72-23	12699-12709	0.01/69078	_
72-24	12710-12711	=	_
72-25	12712-12717	1.45e	_
72-26	12718-12719	−	_
72-27	12720-12721	7	_
72-28	12722-12723	)	_
72-29	12724-12728	used	_
72-30	12729-12731	in	_
72-31	12732-12742	one-sample	_
72-32	12743-12750	t-tests	_
72-33	12751-12753	on	_
72-34	12754-12758	each	_
72-35	12759-12764	group	_
72-36	12765-12767	's	_
72-37	12768-12776	subjects	_
72-38	12777-12780	was	_
72-39	12781-12783	as	_
72-40	12784-12788	same	_
72-41	12789-12791	as	_
72-42	12792-12795	the	_
72-43	12796-12805	parameter	_
72-44	12806-12808	of	_
72-45	12809-12819	one-sample	_
72-46	12820-12827	t-tests	_
72-47	12828-12830	on	_
72-48	12831-12834	all	_
72-49	12835-12843	subjects	_
72-50	12844-12846	of	_
72-51	12847-12852	three	_
72-52	12853-12859	groups	_
72-53	12860-12861	.	_

Text=We then combined the three masks obtained separately from the three groups in order to compare them with the mask obtained using the whole dataset.
73-1	12862-12864	We	_
73-2	12865-12869	then	_
73-3	12870-12878	combined	_
73-4	12879-12882	the	_
73-5	12883-12888	three	_
73-6	12889-12894	masks	_
73-7	12895-12903	obtained	_
73-8	12904-12914	separately	_
73-9	12915-12919	from	_
73-10	12920-12923	the	_
73-11	12924-12929	three	_
73-12	12930-12936	groups	_
73-13	12937-12939	in	_
73-14	12940-12945	order	_
73-15	12946-12948	to	_
73-16	12949-12956	compare	_
73-17	12957-12961	them	_
73-18	12962-12966	with	_
73-19	12967-12970	the	_
73-20	12971-12975	mask	_
73-21	12976-12984	obtained	_
73-22	12985-12990	using	_
73-23	12991-12994	the	_
73-24	12995-13000	whole	_
73-25	13001-13008	dataset	_
73-26	13009-13010	.	_

Text=In the second step, we defined 19 non-overlapping patterns (see Fig.
74-1	13011-13013	In	_
74-2	13014-13017	the	_
74-3	13018-13024	second	_
74-4	13025-13029	step	_
74-5	13030-13031	,	_
74-6	13032-13034	we	_
74-7	13035-13042	defined	_
74-8	13043-13045	19	_
74-9	13046-13061	non-overlapping	_
74-10	13062-13070	patterns	_
74-11	13071-13072	(	_
74-12	13073-13076	see	_
74-13	13077-13080	Fig	_
74-14	13081-13082	.	_

Text=1) that reflect all possible significant differences among the three groups based on statistical analysis results from two-tailed two-sample t-tests, and then identified regions including voxels coinciding with each pattern.
75-1	13083-13084	1	_
75-2	13085-13086	)	_
75-3	13087-13091	that	_
75-4	13092-13099	reflect	_
75-5	13100-13103	all	_
75-6	13104-13112	possible	_
75-7	13113-13124	significant	_
75-8	13125-13136	differences	_
75-9	13137-13142	among	_
75-10	13143-13146	the	_
75-11	13147-13152	three	_
75-12	13153-13159	groups	_
75-13	13160-13165	based	_
75-14	13166-13168	on	_
75-15	13169-13180	statistical	_
75-16	13181-13189	analysis	_
75-17	13190-13197	results	_
75-18	13198-13202	from	_
75-19	13203-13213	two-tailed	_
75-20	13214-13224	two-sample	_
75-21	13225-13232	t-tests	_
75-22	13233-13234	,	_
75-23	13235-13238	and	_
75-24	13239-13243	then	_
75-25	13244-13254	identified	_
75-26	13255-13262	regions	_
75-27	13263-13272	including	_
75-28	13273-13279	voxels	_
75-29	13280-13290	coinciding	_
75-30	13291-13295	with	_
75-31	13296-13300	each	_
75-32	13301-13308	pattern	_
75-33	13309-13310	.	_

Text=Specifically, for each significant voxel in the network mask identified, we performed two-tailed two-sample t-tests (p <0.05) on its Z-score for three pairs of groups (HC vs. CHR, CHR vs. ESZ, and HC vs. ESZ) and then examined whether its Z-score exhibited one of 19 characteristic patterns.
76-1	13311-13323	Specifically	_
76-2	13324-13325	,	_
76-3	13326-13329	for	_
76-4	13330-13334	each	_
76-5	13335-13346	significant	_
76-6	13347-13352	voxel	_
76-7	13353-13355	in	_
76-8	13356-13359	the	_
76-9	13360-13367	network	_
76-10	13368-13372	mask	_
76-11	13373-13383	identified	_
76-12	13384-13385	,	_
76-13	13386-13388	we	_
76-14	13389-13398	performed	_
76-15	13399-13409	two-tailed	_
76-16	13410-13420	two-sample	_
76-17	13421-13428	t-tests	_
76-18	13429-13430	(	_
76-19	13431-13432	p	_
76-20	13433-13434	<	_
76-21	13435-13439	0.05	_
76-22	13440-13441	)	_
76-23	13442-13444	on	_
76-24	13445-13448	its	_
76-25	13449-13456	Z-score	_
76-26	13457-13460	for	_
76-27	13461-13466	three	_
76-28	13467-13472	pairs	_
76-29	13473-13475	of	_
76-30	13476-13482	groups	_
76-31	13483-13484	(	_
76-32	13485-13487	HC	_
76-33	13488-13491	vs.	_
76-34	13492-13495	CHR	_
76-35	13496-13497	,	_
76-36	13498-13501	CHR	_
76-37	13502-13505	vs.	_
76-38	13506-13509	ESZ	_
76-39	13510-13511	,	_
76-40	13512-13515	and	_
76-41	13516-13518	HC	_
76-42	13519-13522	vs.	_
76-43	13523-13526	ESZ	_
76-44	13527-13528	)	_
76-45	13529-13532	and	_
76-46	13533-13537	then	_
76-47	13538-13546	examined	_
76-48	13547-13554	whether	_
76-49	13555-13558	its	_
76-50	13559-13566	Z-score	_
76-51	13567-13576	exhibited	_
76-52	13577-13580	one	_
76-53	13581-13583	of	_
76-54	13584-13586	19	_
76-55	13587-13601	characteristic	_
76-56	13602-13610	patterns	_
76-57	13611-13612	.	_

Text=Among the 19 patterns, two patterns (Fig.
77-1	13613-13618	Among	_
77-2	13619-13622	the	_
77-3	13623-13625	19	_
77-4	13626-13634	patterns	_
77-5	13635-13636	,	_
77-6	13637-13640	two	_
77-7	13641-13649	patterns	_
77-8	13650-13651	(	_
77-9	13652-13655	Fig	_
77-10	13656-13657	.	_

Text=1A–B) corresponded to strictly decreasing and strictly increasing Z-scores from HC to CHR to ESZ.
78-1	13658-13662	1A–B	_
78-2	13663-13664	)	_
78-3	13665-13677	corresponded	_
78-4	13678-13680	to	_
78-5	13681-13689	strictly	_
78-6	13690-13700	decreasing	_
78-7	13701-13704	and	_
78-8	13705-13713	strictly	_
78-9	13714-13724	increasing	_
78-10	13725-13733	Z-scores	_
78-11	13734-13738	from	_
78-12	13739-13741	HC	_
78-13	13742-13744	to	_
78-14	13745-13748	CHR	_
78-15	13749-13751	to	_
78-16	13752-13755	ESZ	_
78-17	13756-13757	.	_

Text=For example, for the strictly decreasing pattern, t-value> 0 was required for both the HC vs. CHR test and the CHR vs. ESZ test, reflecting significant decreases in Z-scores from the healthy condition to the psychosis-risk state and from the risk-state to full-blown schizophrenia.
79-1	13758-13761	For	_
79-2	13762-13769	example	_
79-3	13770-13771	,	_
79-4	13772-13775	for	_
79-5	13776-13779	the	_
79-6	13780-13788	strictly	_
79-7	13789-13799	decreasing	_
79-8	13800-13807	pattern	_
79-9	13808-13809	,	_
79-10	13810-13817	t-value	_
79-11	13818-13819	>	_
79-12	13820-13821	0	_
79-13	13822-13825	was	_
79-14	13826-13834	required	_
79-15	13835-13838	for	_
79-16	13839-13843	both	_
79-17	13844-13847	the	_
79-18	13848-13850	HC	_
79-19	13851-13854	vs.	_
79-20	13855-13858	CHR	_
79-21	13859-13863	test	_
79-22	13864-13867	and	_
79-23	13868-13871	the	_
79-24	13872-13875	CHR	_
79-25	13876-13879	vs.	_
79-26	13880-13883	ESZ	_
79-27	13884-13888	test	_
79-28	13889-13890	,	_
79-29	13891-13901	reflecting	_
79-30	13902-13913	significant	_
79-31	13914-13923	decreases	_
79-32	13924-13926	in	_
79-33	13927-13935	Z-scores	_
79-34	13936-13940	from	_
79-35	13941-13944	the	_
79-36	13945-13952	healthy	_
79-37	13953-13962	condition	_
79-38	13963-13965	to	_
79-39	13966-13969	the	_
79-40	13970-13984	psychosis-risk	_
79-41	13985-13990	state	_
79-42	13991-13994	and	_
79-43	13995-13999	from	_
79-44	14000-14003	the	_
79-45	14004-14014	risk-state	_
79-46	14015-14017	to	_
79-47	14018-14028	full-blown	_
79-48	14029-14042	schizophrenia	_
79-49	14043-14044	.	_

Text=Four patterns (Fig.
80-1	14045-14049	Four	_
80-2	14050-14058	patterns	_
80-3	14059-14060	(	_
80-4	14061-14064	Fig	_
80-5	14065-14066	.	_

Text=1C–F) involved situations where the ESZ or HC group was significantly lower or significantly higher than the other two groups.
81-1	14067-14071	1C–F	_
81-2	14072-14073	)	_
81-3	14074-14082	involved	_
81-4	14083-14093	situations	_
81-5	14094-14099	where	_
81-6	14100-14103	the	_
81-7	14104-14107	ESZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
81-8	14108-14110	or	_
81-9	14111-14113	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
81-10	14114-14119	group	_
81-11	14120-14123	was	_
81-12	14124-14137	significantly	_
81-13	14138-14143	lower	_
81-14	14144-14146	or	_
81-15	14147-14160	significantly	_
81-16	14161-14167	higher	_
81-17	14168-14172	than	_
81-18	14173-14176	the	_
81-19	14177-14182	other	_
81-20	14183-14186	two	_
81-21	14187-14193	groups	_
81-22	14194-14195	.	_

Text=For example, in the ESZ-decreasing pattern, t-value> 0 was required for both the HC vs. ESZ and CHR vs. ESZ comparisons, with no significant difference between the HC and CHR groups.
82-1	14196-14199	For	_
82-2	14200-14207	example	_
82-3	14208-14209	,	_
82-4	14210-14212	in	_
82-5	14213-14216	the	_
82-6	14217-14231	ESZ-decreasing	_
82-7	14232-14239	pattern	_
82-8	14240-14241	,	_
82-9	14242-14249	t-value	_
82-10	14250-14251	>	_
82-11	14252-14253	0	_
82-12	14254-14257	was	_
82-13	14258-14266	required	_
82-14	14267-14270	for	_
82-15	14271-14275	both	_
82-16	14276-14279	the	_
82-17	14280-14282	HC	_
82-18	14283-14286	vs.	_
82-19	14287-14290	ESZ	_
82-20	14291-14294	and	_
82-21	14295-14298	CHR	_
82-22	14299-14302	vs.	_
82-23	14303-14306	ESZ	_
82-24	14307-14318	comparisons	_
82-25	14319-14320	,	_
82-26	14321-14325	with	_
82-27	14326-14328	no	_
82-28	14329-14340	significant	_
82-29	14341-14351	difference	_
82-30	14352-14359	between	_
82-31	14360-14363	the	_
82-32	14364-14366	HC	_
82-33	14367-14370	and	_
82-34	14371-14374	CHR	_
82-35	14375-14381	groups	_
82-36	14382-14383	.	_

Text=Six additional patterns (Fig.
83-1	14384-14387	Six	_
83-2	14388-14398	additional	_
83-3	14399-14407	patterns	_
83-4	14408-14409	(	_
83-5	14410-14413	Fig	_
83-6	14414-14415	.	_

Text=2G–L) were CHR-unique alteration related patterns in which the CHR group had significantly lower or higher Z-scores than the other two groups.
84-1	14416-14420	2G–L	_
84-2	14421-14422	)	_
84-3	14423-14427	were	_
84-4	14428-14438	CHR-unique	_
84-5	14439-14449	alteration	_
84-6	14450-14457	related	_
84-7	14458-14466	patterns	_
84-8	14467-14469	in	_
84-9	14470-14475	which	_
84-10	14476-14479	the	_
84-11	14480-14483	CHR	_
84-12	14484-14489	group	_
84-13	14490-14493	had	_
84-14	14494-14507	significantly	_
84-15	14508-14513	lower	_
84-16	14514-14516	or	_
84-17	14517-14523	higher	_
84-18	14524-14532	Z-scores	_
84-19	14533-14537	than	_
84-20	14538-14541	the	_
84-21	14542-14547	other	_
84-22	14548-14551	two	_
84-23	14552-14558	groups	_
84-24	14559-14560	.	_

Text=For example, in terms of the CHR-decreasing pattern 1 (Fig.
85-1	14561-14564	For	_
85-2	14565-14572	example	_
85-3	14573-14574	,	_
85-4	14575-14577	in	_
85-5	14578-14583	terms	_
85-6	14584-14586	of	_
85-7	14587-14590	the	_
85-8	14591-14605	CHR-decreasing	_
85-9	14606-14613	pattern	_
85-10	14614-14615	1	_
85-11	14616-14617	(	_
85-12	14618-14621	Fig	_
85-13	14622-14623	.	_

Text=2G), we required t-value> 0 for the HC vs. CHR comparison as well as t-value <0 for the CHR vs. ESZ comparison, with no significant difference between the ESZ and HC groups.
86-1	14624-14626	2G	_
86-2	14627-14628	)	_
86-3	14629-14630	,	_
86-4	14631-14633	we	_
86-5	14634-14642	required	_
86-6	14643-14650	t-value	_
86-7	14651-14652	>	_
86-8	14653-14654	0	_
86-9	14655-14658	for	_
86-10	14659-14662	the	_
86-11	14663-14665	HC	_
86-12	14666-14669	vs.	_
86-13	14670-14673	CHR	_
86-14	14674-14684	comparison	_
86-15	14685-14687	as	_
86-16	14688-14692	well	_
86-17	14693-14695	as	_
86-18	14696-14703	t-value	_
86-19	14704-14705	<	_
86-20	14706-14707	0	_
86-21	14708-14711	for	_
86-22	14712-14715	the	_
86-23	14716-14719	CHR	_
86-24	14720-14723	vs.	_
86-25	14724-14727	ESZ	_
86-26	14728-14738	comparison	_
86-27	14739-14740	,	_
86-28	14741-14745	with	_
86-29	14746-14748	no	_
86-30	14749-14760	significant	_
86-31	14761-14771	difference	_
86-32	14772-14779	between	_
86-33	14780-14783	the	_
86-34	14784-14787	ESZ	_
86-35	14788-14791	and	_
86-36	14792-14794	HC	_
86-37	14795-14801	groups	_
86-38	14802-14803	.	_

Text=There were also six patterns (Fig.
87-1	14804-14809	There	_
87-2	14810-14814	were	_
87-3	14815-14819	also	_
87-4	14820-14823	six	_
87-5	14824-14832	patterns	_
87-6	14833-14834	(	_
87-7	14835-14838	Fig	_
87-8	14839-14840	.	_

Text=1M–R) in which only one pair of groups showed a group difference.
88-1	14841-14845	1M–R	_
88-2	14846-14847	)	_
88-3	14848-14850	in	_
88-4	14851-14856	which	_
88-5	14857-14861	only	_
88-6	14862-14865	one	_
88-7	14866-14870	pair	_
88-8	14871-14873	of	_
88-9	14874-14880	groups	_
88-10	14881-14887	showed	_
88-11	14888-14889	a	_
88-12	14890-14895	group	_
88-13	14896-14906	difference	_
88-14	14907-14908	.	_

Text=Taking the HC> ESZ pattern for an example, t-value> 0 for the HC vs. ESZ comparison and no group differences for other comparisons were required.
89-1	14909-14915	Taking	_
89-2	14916-14919	the	_
89-3	14920-14922	HC	_
89-4	14923-14924	>	_
89-5	14925-14928	ESZ	_
89-6	14929-14936	pattern	_
89-7	14937-14940	for	_
89-8	14941-14943	an	_
89-9	14944-14951	example	_
89-10	14952-14953	,	_
89-11	14954-14961	t-value	_
89-12	14962-14963	>	_
89-13	14964-14965	0	_
89-14	14966-14969	for	_
89-15	14970-14973	the	_
89-16	14974-14976	HC	_
89-17	14977-14980	vs.	_
89-18	14981-14984	ESZ	_
89-19	14985-14995	comparison	_
89-20	14996-14999	and	_
89-21	15000-15002	no	_
89-22	15003-15008	group	_
89-23	15009-15020	differences	_
89-24	15021-15024	for	_
89-25	15025-15030	other	_
89-26	15031-15042	comparisons	_
89-27	15043-15047	were	_
89-28	15048-15056	required	_
89-29	15057-15058	.	_

Text=Finally, a no-difference pattern (Fig.
90-1	15059-15066	Finally	_
90-2	15067-15068	,	_
90-3	15069-15070	a	_
90-4	15071-15084	no-difference	_
90-5	15085-15092	pattern	_
90-6	15093-15094	(	_
90-7	15095-15098	Fig	_
90-8	15099-15100	.	_

Text=2S) was possible, where all three groups showed no significant differences (i.e., p> 0.05 for all comparisons).
91-1	15101-15103	2S	_
91-2	15104-15105	)	_
91-3	15106-15109	was	_
91-4	15110-15118	possible	_
91-5	15119-15120	,	_
91-6	15121-15126	where	_
91-7	15127-15130	all	_
91-8	15131-15136	three	_
91-9	15137-15143	groups	_
91-10	15144-15150	showed	_
91-11	15151-15153	no	_
91-12	15154-15165	significant	_
91-13	15166-15177	differences	_
91-14	15178-15179	(	_
91-15	15180-15184	i.e.	_
91-16	15185-15186	,	_
91-17	15187-15188	p	_
91-18	15189-15190	>	_
91-19	15191-15195	0.05	_
91-20	15196-15199	for	_
91-21	15200-15203	all	_
91-22	15204-15215	comparisons	_
91-23	15216-15217	)	_
91-24	15218-15219	.	_

Text=Regarding each pattern, the associated voxels were identified and then corrected (p <0.05) for multiple comparisons using Monte Carlo simulation (N = 1000) to obtain regions each of which were spatially continuous.
92-1	15220-15229	Regarding	_
92-2	15230-15234	each	_
92-3	15235-15242	pattern	_
92-4	15243-15244	,	_
92-5	15245-15248	the	_
92-6	15249-15259	associated	_
92-7	15260-15266	voxels	_
92-8	15267-15271	were	_
92-9	15272-15282	identified	_
92-10	15283-15286	and	_
92-11	15287-15291	then	_
92-12	15292-15301	corrected	_
92-13	15302-15303	(	_
92-14	15304-15305	p	_
92-15	15306-15307	<	_
92-16	15308-15312	0.05	_
92-17	15313-15314	)	_
92-18	15315-15318	for	_
92-19	15319-15327	multiple	_
92-20	15328-15339	comparisons	_
92-21	15340-15345	using	_
92-22	15346-15351	Monte	_
92-23	15352-15357	Carlo	_
92-24	15358-15368	simulation	_
92-25	15369-15370	(	_
92-26	15371-15372	N	_
92-27	15373-15374	=	_
92-28	15375-15379	1000	_
92-29	15380-15381	)	_
92-30	15382-15384	to	_
92-31	15385-15391	obtain	_
92-32	15392-15399	regions	_
92-33	15400-15404	each	_
92-34	15405-15407	of	_
92-35	15408-15413	which	_
92-36	15414-15418	were	_
92-37	15419-15428	spatially	_
92-38	15429-15439	continuous	_
92-39	15440-15441	.	_

Text=Thus, each remaining region was required to have a size greater than a given voxel number that was determined by the threshold p <0.05 and the network mask from the voxel-wise one-sample t-tests using 1000 Monte Carlo simulations.
93-1	15442-15446	Thus	_
93-2	15447-15448	,	_
93-3	15449-15453	each	_
93-4	15454-15463	remaining	_
93-5	15464-15470	region	_
93-6	15471-15474	was	_
93-7	15475-15483	required	_
93-8	15484-15486	to	_
93-9	15487-15491	have	_
93-10	15492-15493	a	_
93-11	15494-15498	size	_
93-12	15499-15506	greater	_
93-13	15507-15511	than	_
93-14	15512-15513	a	_
93-15	15514-15519	given	_
93-16	15520-15525	voxel	_
93-17	15526-15532	number	_
93-18	15533-15537	that	_
93-19	15538-15541	was	_
93-20	15542-15552	determined	_
93-21	15553-15555	by	_
93-22	15556-15559	the	_
93-23	15560-15569	threshold	_
93-24	15570-15571	p	_
93-25	15572-15573	<	_
93-26	15574-15578	0.05	_
93-27	15579-15582	and	_
93-28	15583-15586	the	_
93-29	15587-15594	network	_
93-30	15595-15599	mask	_
93-31	15600-15604	from	_
93-32	15605-15608	the	_
93-33	15609-15619	voxel-wise	_
93-34	15620-15630	one-sample	_
93-35	15631-15638	t-tests	_
93-36	15639-15644	using	_
93-37	15645-15649	1000	_
93-38	15650-15655	Monte	_
93-39	15656-15661	Carlo	_
93-40	15662-15673	simulations	_
93-41	15674-15675	.	_

Text=Except for the last pattern representing no significant difference across groups, we named the identified regions as significant discriminative regions (SDRs) within the associated INs.
94-1	15676-15682	Except	_
94-2	15683-15686	for	_
94-3	15687-15690	the	_
94-4	15691-15695	last	_
94-5	15696-15703	pattern	_
94-6	15704-15716	representing	_
94-7	15717-15719	no	_
94-8	15720-15731	significant	_
94-9	15732-15742	difference	_
94-10	15743-15749	across	_
94-11	15750-15756	groups	_
94-12	15757-15758	,	_
94-13	15759-15761	we	_
94-14	15762-15767	named	_
94-15	15768-15771	the	_
94-16	15772-15782	identified	_
94-17	15783-15790	regions	_
94-18	15791-15793	as	_
94-19	15794-15805	significant	_
94-20	15806-15820	discriminative	_
94-21	15821-15828	regions	_
94-22	15829-15830	(	_
94-23	15831-15835	SDRs	_
94-24	15836-15837	)	_
94-25	15838-15844	within	_
94-26	15845-15848	the	_
94-27	15849-15859	associated	_
94-28	15860-15863	INs	_
94-29	15864-15865	.	_

Text=In our work, we applied two-tailed two-sample t-tests to define the changing patterns because we cannot make a hypothesis that one group (e.g., HC) shows higher (or lower) Z-scores in network than the other group (e.g., CHR).
95-1	15866-15868	In	_
95-2	15869-15872	our	_
95-3	15873-15877	work	_
95-4	15878-15879	,	_
95-5	15880-15882	we	_
95-6	15883-15890	applied	_
95-7	15891-15901	two-tailed	_
95-8	15902-15912	two-sample	_
95-9	15913-15920	t-tests	_
95-10	15921-15923	to	_
95-11	15924-15930	define	_
95-12	15931-15934	the	_
95-13	15935-15943	changing	_
95-14	15944-15952	patterns	_
95-15	15953-15960	because	_
95-16	15961-15963	we	_
95-17	15964-15967	can	_
95-18	15968-15971	not	_
95-19	15972-15976	make	_
95-20	15977-15978	a	_
95-21	15979-15989	hypothesis	_
95-22	15990-15994	that	_
95-23	15995-15998	one	_
95-24	15999-16004	group	_
95-25	16005-16006	(	_
95-26	16007-16011	e.g.	_
95-27	16012-16013	,	_
95-28	16014-16016	HC	_
95-29	16017-16018	)	_
95-30	16019-16024	shows	_
95-31	16025-16031	higher	_
95-32	16032-16033	(	_
95-33	16034-16036	or	_
95-34	16037-16042	lower	_
95-35	16043-16044	)	_
95-36	16045-16053	Z-scores	_
95-37	16054-16056	in	_
95-38	16057-16064	network	_
95-39	16065-16069	than	_
95-40	16070-16073	the	_
95-41	16074-16079	other	_
95-42	16080-16085	group	_
95-43	16086-16087	(	_
95-44	16088-16092	e.g.	_
95-45	16093-16094	,	_
95-46	16095-16098	CHR	_
95-47	16099-16100	)	_
95-48	16101-16102	.	_

Text=We are testing for the possibility of the relationship in both directions (i.e., the possibility of one group shows higher and lower Z-scores than the other group).
96-1	16103-16105	We	_
96-2	16106-16109	are	_
96-3	16110-16117	testing	_
96-4	16118-16121	for	_
96-5	16122-16125	the	_
96-6	16126-16137	possibility	_
96-7	16138-16140	of	_
96-8	16141-16144	the	_
96-9	16145-16157	relationship	_
96-10	16158-16160	in	_
96-11	16161-16165	both	_
96-12	16166-16176	directions	_
96-13	16177-16178	(	_
96-14	16179-16183	i.e.	_
96-15	16184-16185	,	_
96-16	16186-16189	the	_
96-17	16190-16201	possibility	_
96-18	16202-16204	of	_
96-19	16205-16208	one	_
96-20	16209-16214	group	_
96-21	16215-16220	shows	_
96-22	16221-16227	higher	_
96-23	16228-16231	and	_
96-24	16232-16237	lower	_
96-25	16238-16246	Z-scores	_
96-26	16247-16251	than	_
96-27	16252-16255	the	_
96-28	16256-16261	other	_
96-29	16262-16267	group	_
96-30	16268-16269	)	_
96-31	16270-16271	.	_

Text=In the third step, for each SDR including voxels with the same pattern in a specific IN, we tested whether its co-activation differed significantly among the HC, CHR and ESZ groups.
97-1	16272-16274	In	_
97-2	16275-16278	the	_
97-3	16279-16284	third	_
97-4	16285-16289	step	_
97-5	16290-16291	,	_
97-6	16292-16295	for	_
97-7	16296-16300	each	_
97-8	16301-16304	SDR	_
97-9	16305-16314	including	_
97-10	16315-16321	voxels	_
97-11	16322-16326	with	_
97-12	16327-16330	the	_
97-13	16331-16335	same	_
97-14	16336-16343	pattern	_
97-15	16344-16346	in	_
97-16	16347-16348	a	_
97-17	16349-16357	specific	_
97-18	16358-16360	IN	_
97-19	16361-16362	,	_
97-20	16363-16365	we	_
97-21	16366-16372	tested	_
97-22	16373-16380	whether	_
97-23	16381-16384	its	_
97-24	16385-16398	co-activation	_
97-25	16399-16407	differed	_
97-26	16408-16421	significantly	_
97-27	16422-16427	among	_
97-28	16428-16431	the	_
97-29	16432-16434	HC	_
97-30	16435-16436	,	_
97-31	16437-16440	CHR	_
97-32	16441-16444	and	_
97-33	16445-16448	ESZ	_
97-34	16449-16455	groups	_
97-35	16456-16457	.	_

Text=Based on the results from the above mentioned voxel-wise two-sample t-tests of different voxels in one SDR, we applied a Fisher's combined probability test to measure the group difference of each SDR's co-activation, resulting in a combined p-value for any comparison between two groups (e.g., HC vs. CHR).
98-1	16458-16463	Based	_
98-2	16464-16466	on	_
98-3	16467-16470	the	_
98-4	16471-16478	results	_
98-5	16479-16483	from	_
98-6	16484-16487	the	_
98-7	16488-16493	above	_
98-8	16494-16503	mentioned	_
98-9	16504-16514	voxel-wise	_
98-10	16515-16525	two-sample	_
98-11	16526-16533	t-tests	_
98-12	16534-16536	of	_
98-13	16537-16546	different	_
98-14	16547-16553	voxels	_
98-15	16554-16556	in	_
98-16	16557-16560	one	_
98-17	16561-16564	SDR	_
98-18	16565-16566	,	_
98-19	16567-16569	we	_
98-20	16570-16577	applied	_
98-21	16578-16579	a	_
98-22	16580-16586	Fisher	_
98-23	16587-16589	's	_
98-24	16590-16598	combined	_
98-25	16599-16610	probability	_
98-26	16611-16615	test	_
98-27	16616-16618	to	_
98-28	16619-16626	measure	_
98-29	16627-16630	the	_
98-30	16631-16636	group	_
98-31	16637-16647	difference	_
98-32	16648-16650	of	_
98-33	16651-16655	each	_
98-34	16656-16659	SDR	_
98-35	16660-16662	's	_
98-36	16663-16676	co-activation	_
98-37	16677-16678	,	_
98-38	16679-16688	resulting	_
98-39	16689-16691	in	_
98-40	16692-16693	a	_
98-41	16694-16702	combined	_
98-42	16703-16710	p-value	_
98-43	16711-16714	for	_
98-44	16715-16718	any	_
98-45	16719-16729	comparison	_
98-46	16730-16737	between	_
98-47	16738-16741	two	_
98-48	16742-16748	groups	_
98-49	16749-16750	(	_
98-50	16751-16755	e.g.	_
98-51	16756-16757	,	_
98-52	16758-16760	HC	_
98-53	16761-16764	vs.	_
98-54	16765-16768	CHR	_
98-55	16769-16770	)	_
98-56	16771-16772	.	_

Text=Since Fisher's combined probability test was proposed originally under an assumption of independence among separate tests, we also performed a non-parametric combination method including 10,000 permutations as a supplement.
99-1	16773-16778	Since	_
99-2	16779-16785	Fisher	_
99-3	16786-16788	's	_
99-4	16789-16797	combined	_
99-5	16798-16809	probability	_
99-6	16810-16814	test	_
99-7	16815-16818	was	_
99-8	16819-16827	proposed	_
99-9	16828-16838	originally	_
99-10	16839-16844	under	_
99-11	16845-16847	an	_
99-12	16848-16858	assumption	_
99-13	16859-16861	of	_
99-14	16862-16874	independence	_
99-15	16875-16880	among	_
99-16	16881-16889	separate	_
99-17	16890-16895	tests	_
99-18	16896-16897	,	_
99-19	16898-16900	we	_
99-20	16901-16905	also	_
99-21	16906-16915	performed	_
99-22	16916-16917	a	_
99-23	16918-16932	non-parametric	_
99-24	16933-16944	combination	_
99-25	16945-16951	method	_
99-26	16952-16961	including	_
99-27	16962-16968	10,000	_
99-28	16969-16981	permutations	_
99-29	16982-16984	as	_
99-30	16985-16986	a	_
99-31	16987-16997	supplement	_
99-32	16998-16999	.	_

Text=The non-parametric combination procedure works even when independence is untenable.
100-1	17000-17003	The	_
100-2	17004-17018	non-parametric	_
100-3	17019-17030	combination	_
100-4	17031-17040	procedure	_
100-5	17041-17046	works	_
100-6	17047-17051	even	_
100-7	17052-17056	when	_
100-8	17057-17069	independence	_
100-9	17070-17072	is	_
100-10	17073-17082	untenable	_
100-11	17083-17084	.	_

Text=The detailed steps for the non-parametric combination method are described in the Supplementary materials.
101-1	17085-17088	The	_
101-2	17089-17097	detailed	_
101-3	17098-17103	steps	_
101-4	17104-17107	for	_
101-5	17108-17111	the	_
101-6	17112-17126	non-parametric	_
101-7	17127-17138	combination	_
101-8	17139-17145	method	_
101-9	17146-17149	are	_
101-10	17150-17159	described	_
101-11	17160-17162	in	_
101-12	17163-17166	the	_
101-13	17167-17180	Supplementary	_
101-14	17181-17190	materials	_
101-15	17191-17192	.	_

Text=If the combined p-value of one comparison between two groups was smaller than 0.05/3, we regarded the co-activation in SDR significantly different between the two groups.
102-1	17193-17195	If	_
102-2	17196-17199	the	_
102-3	17200-17208	combined	_
102-4	17209-17216	p-value	_
102-5	17217-17219	of	_
102-6	17220-17223	one	_
102-7	17224-17234	comparison	_
102-8	17235-17242	between	_
102-9	17243-17246	two	_
102-10	17247-17253	groups	_
102-11	17254-17257	was	_
102-12	17258-17265	smaller	_
102-13	17266-17270	than	_
102-14	17271-17277	0.05/3	_
102-15	17278-17279	,	_
102-16	17280-17282	we	_
102-17	17283-17291	regarded	_
102-18	17292-17295	the	_
102-19	17296-17309	co-activation	_
102-20	17310-17312	in	_
102-21	17313-17316	SDR	_
102-22	17317-17330	significantly	_
102-23	17331-17340	different	_
102-24	17341-17348	between	_
102-25	17349-17352	the	_
102-26	17353-17356	two	_
102-27	17357-17363	groups	_
102-28	17364-17365	.	_

Text=Additionally, since the mean Z-score within voxels of each SDR can be used to reflect co-activation strength in the SDR, we calculated the Pearson correlation between the co-activation strengths of each SDR within one specific IN and the symptom severity ratings (in Table 1) for the CHR group and the ESZ group to explore the association between network measures and symptoms.
103-1	17366-17378	Additionally	_
103-2	17379-17380	,	_
103-3	17381-17386	since	_
103-4	17387-17390	the	_
103-5	17391-17395	mean	_
103-6	17396-17403	Z-score	_
103-7	17404-17410	within	_
103-8	17411-17417	voxels	_
103-9	17418-17420	of	_
103-10	17421-17425	each	_
103-11	17426-17429	SDR	_
103-12	17430-17433	can	_
103-13	17434-17436	be	_
103-14	17437-17441	used	_
103-15	17442-17444	to	_
103-16	17445-17452	reflect	_
103-17	17453-17466	co-activation	_
103-18	17467-17475	strength	_
103-19	17476-17478	in	_
103-20	17479-17482	the	_
103-21	17483-17486	SDR	_
103-22	17487-17488	,	_
103-23	17489-17491	we	_
103-24	17492-17502	calculated	_
103-25	17503-17506	the	_
103-26	17507-17514	Pearson	_
103-27	17515-17526	correlation	_
103-28	17527-17534	between	_
103-29	17535-17538	the	_
103-30	17539-17552	co-activation	_
103-31	17553-17562	strengths	_
103-32	17563-17565	of	_
103-33	17566-17570	each	_
103-34	17571-17574	SDR	_
103-35	17575-17581	within	_
103-36	17582-17585	one	_
103-37	17586-17594	specific	_
103-38	17595-17597	IN	_
103-39	17598-17601	and	_
103-40	17602-17605	the	_
103-41	17606-17613	symptom	_
103-42	17614-17622	severity	_
103-43	17623-17630	ratings	_
103-44	17631-17632	(	_
103-45	17633-17635	in	_
103-46	17636-17641	Table	_
103-47	17642-17643	1	_
103-48	17644-17645	)	_
103-49	17646-17649	for	_
103-50	17650-17653	the	_
103-51	17654-17657	CHR	_
103-52	17658-17663	group	_
103-53	17664-17667	and	_
103-54	17668-17671	the	_
103-55	17672-17675	ESZ	_
103-56	17676-17681	group	_
103-57	17682-17684	to	_
103-58	17685-17692	explore	_
103-59	17693-17696	the	_
103-60	17697-17708	association	_
103-61	17709-17716	between	_
103-62	17717-17724	network	_
103-63	17725-17733	measures	_
103-64	17734-17737	and	_
103-65	17738-17746	symptoms	_
103-66	17747-17748	.	_

Text=The significance level was set to p <0.05 for the correlation analyses.
104-1	17749-17752	The	_
104-2	17753-17765	significance	_
104-3	17766-17771	level	_
104-4	17772-17775	was	_
104-5	17776-17779	set	_
104-6	17780-17782	to	_
104-7	17783-17784	p	_
104-8	17785-17786	<	_
104-9	17787-17791	0.05	_
104-10	17792-17795	for	_
104-11	17796-17799	the	_
104-12	17800-17811	correlation	_
104-13	17812-17820	analyses	_
104-14	17821-17822	.	_

Text=The whole analysis framework is shown in Fig.
105-1	17823-17826	The	_
105-2	17827-17832	whole	_
105-3	17833-17841	analysis	_
105-4	17842-17851	framework	_
105-5	17852-17854	is	_
105-6	17855-17860	shown	_
105-7	17861-17863	in	_
105-8	17864-17867	Fig	_
105-9	17868-17869	.	_

Text=2.
106-1	17870-17871	2	_
106-2	17872-17873	.	_

Text=We also tested if medication has significant effects on the identified measures showing group differences.
107-1	17874-17876	We	_
107-2	17877-17881	also	_
107-3	17882-17888	tested	_
107-4	17889-17891	if	_
107-5	17892-17902	medication	_
107-6	17903-17906	has	_
107-7	17907-17918	significant	_
107-8	17919-17926	effects	_
107-9	17927-17929	on	_
107-10	17930-17933	the	_
107-11	17934-17944	identified	_
107-12	17945-17953	measures	_
107-13	17954-17961	showing	_
107-14	17962-17967	group	_
107-15	17968-17979	differences	_
107-16	17980-17981	.	_

Text=First, we converted all anti-psychotic data to their respective chlorpromazine (CPZ) dosage equivalents for ESZ patients with available dose-level medication data.
108-1	17982-17987	First	_
108-2	17988-17989	,	_
108-3	17990-17992	we	_
108-4	17993-18002	converted	_
108-5	18003-18006	all	_
108-6	18007-18021	anti-psychotic	_
108-7	18022-18026	data	_
108-8	18027-18029	to	_
108-9	18030-18035	their	_
108-10	18036-18046	respective	_
108-11	18047-18061	chlorpromazine	_
108-12	18062-18063	(	_
108-13	18064-18067	CPZ	_
108-14	18068-18069	)	_
108-15	18070-18076	dosage	_
108-16	18077-18088	equivalents	_
108-17	18089-18092	for	_
108-18	18093-18096	ESZ	_
108-19	18097-18105	patients	_
108-20	18106-18110	with	_
108-21	18111-18120	available	_
108-22	18121-18131	dose-level	_
108-23	18132-18142	medication	_
108-24	18143-18147	data	_
108-25	18148-18149	.	_

Text=Only one ESZ patient had no CPZ data.
109-1	18150-18154	Only	_
109-2	18155-18158	one	_
109-3	18159-18162	ESZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
109-4	18163-18170	patient	_
109-5	18171-18174	had	_
109-6	18175-18177	no	_
109-7	18178-18181	CPZ	_
109-8	18182-18186	data	_
109-9	18187-18188	.	_

Text=We then used a non-parametric Spearman's rank correlation method to evaluate the association between the CPZ equivalent and the co-activation (reflected by the mean Z-score) of each SDR (p <0.05 with Bonferroni correction, i.e., p-value threshold = 0.05/the number of all SDRs) for ESZ patients.
110-1	18189-18191	We	_
110-2	18192-18196	then	_
110-3	18197-18201	used	_
110-4	18202-18203	a	_
110-5	18204-18218	non-parametric	_
110-6	18219-18227	Spearman	_
110-7	18228-18230	's	_
110-8	18231-18235	rank	_
110-9	18236-18247	correlation	_
110-10	18248-18254	method	_
110-11	18255-18257	to	_
110-12	18258-18266	evaluate	_
110-13	18267-18270	the	_
110-14	18271-18282	association	_
110-15	18283-18290	between	_
110-16	18291-18294	the	_
110-17	18295-18298	CPZ	_
110-18	18299-18309	equivalent	_
110-19	18310-18313	and	_
110-20	18314-18317	the	_
110-21	18318-18331	co-activation	_
110-22	18332-18333	(	_
110-23	18334-18343	reflected	_
110-24	18344-18346	by	_
110-25	18347-18350	the	_
110-26	18351-18355	mean	_
110-27	18356-18363	Z-score	_
110-28	18364-18365	)	_
110-29	18366-18368	of	_
110-30	18369-18373	each	_
110-31	18374-18377	SDR	_
110-32	18378-18379	(	_
110-33	18380-18381	p	_
110-34	18382-18383	<	_
110-35	18384-18388	0.05	_
110-36	18389-18393	with	_
110-37	18394-18404	Bonferroni	_
110-38	18405-18415	correction	_
110-39	18416-18417	,	_
110-40	18418-18422	i.e.	_
110-41	18423-18424	,	_
110-42	18425-18432	p-value	_
110-43	18433-18442	threshold	_
110-44	18443-18444	=	_
110-45	18445-18453	0.05/the	_
110-46	18454-18460	number	_
110-47	18461-18463	of	_
110-48	18464-18467	all	_
110-49	18468-18472	SDRs	_
110-50	18473-18474	)	_
110-51	18475-18478	for	_
110-52	18479-18482	ESZ	_
110-53	18483-18491	patients	_
110-54	18492-18493	.	_

Text=Spearman's rank correlation analysis was applied due to the non-normality of the CPZ variable.
111-1	18494-18502	Spearman	_
111-2	18503-18505	's	_
111-3	18506-18510	rank	_
111-4	18511-18522	correlation	_
111-5	18523-18531	analysis	_
111-6	18532-18535	was	_
111-7	18536-18543	applied	_
111-8	18544-18547	due	_
111-9	18548-18550	to	_
111-10	18551-18554	the	_
111-11	18555-18568	non-normality	_
111-12	18569-18571	of	_
111-13	18572-18575	the	_
111-14	18576-18579	CPZ	_
111-15	18580-18588	variable	_
111-16	18589-18590	.	_

Text=For CHR subjects, we did not perform correlation analysis on the CPZ equivalents due to the small number of the medicated CHR subjects and the relatively noisy property of CPZ equivalents.
112-1	18591-18594	For	_
112-2	18595-18598	CHR	_
112-3	18599-18607	subjects	_
112-4	18608-18609	,	_
112-5	18610-18612	we	_
112-6	18613-18616	did	_
112-7	18617-18620	not	_
112-8	18621-18628	perform	_
112-9	18629-18640	correlation	_
112-10	18641-18649	analysis	_
112-11	18650-18652	on	_
112-12	18653-18656	the	_
112-13	18657-18660	CPZ	_
112-14	18661-18672	equivalents	_
112-15	18673-18676	due	_
112-16	18677-18679	to	_
112-17	18680-18683	the	_
112-18	18684-18689	small	_
112-19	18690-18696	number	_
112-20	18697-18699	of	_
112-21	18700-18703	the	_
112-22	18704-18713	medicated	_
112-23	18714-18717	CHR	_
112-24	18718-18726	subjects	_
112-25	18727-18730	and	_
112-26	18731-18734	the	_
112-27	18735-18745	relatively	_
112-28	18746-18751	noisy	_
112-29	18752-18760	property	_
112-30	18761-18763	of	_
112-31	18764-18767	CPZ	_
112-32	18768-18779	equivalents	_
112-33	18780-18781	.	_

Text=Instead, we examined difference in the co-activation of each SDR between the CHR individuals without medication treatment and the CHR individuals taking medication using a two-tailed two-sample t-test (p <0.05 with Bonferroni correction, i.e., p-value threshold = 0.05/the number of all SDRs).
113-1	18782-18789	Instead	_
113-2	18790-18791	,	_
113-3	18792-18794	we	_
113-4	18795-18803	examined	_
113-5	18804-18814	difference	_
113-6	18815-18817	in	_
113-7	18818-18821	the	_
113-8	18822-18835	co-activation	_
113-9	18836-18838	of	_
113-10	18839-18843	each	_
113-11	18844-18847	SDR	_
113-12	18848-18855	between	_
113-13	18856-18859	the	_
113-14	18860-18863	CHR	_
113-15	18864-18875	individuals	_
113-16	18876-18883	without	_
113-17	18884-18894	medication	_
113-18	18895-18904	treatment	_
113-19	18905-18908	and	_
113-20	18909-18912	the	_
113-21	18913-18916	CHR	_
113-22	18917-18928	individuals	_
113-23	18929-18935	taking	_
113-24	18936-18946	medication	_
113-25	18947-18952	using	_
113-26	18953-18954	a	_
113-27	18955-18965	two-tailed	_
113-28	18966-18976	two-sample	_
113-29	18977-18983	t-test	_
113-30	18984-18985	(	_
113-31	18986-18987	p	_
113-32	18988-18989	<	_
113-33	18990-18994	0.05	_
113-34	18995-18999	with	_
113-35	19000-19010	Bonferroni	_
113-36	19011-19021	correction	_
113-37	19022-19023	,	_
113-38	19024-19028	i.e.	_
113-39	19029-19030	,	_
113-40	19031-19038	p-value	_
113-41	19039-19048	threshold	_
113-42	19049-19050	=	_
113-43	19051-19059	0.05/the	_
113-44	19060-19066	number	_
113-45	19067-19069	of	_
113-46	19070-19073	all	_
113-47	19074-19078	SDRs	_
113-48	19079-19080	)	_
113-49	19081-19082	.	_

